Mathematical Models with Delays for Glucose-Insulin Regulation and Applications in Artificial Pancreas by WU ZIMEI
 
 
MATHEMATICAL MODELS WITH DELAYS FOR GLUCOSE-















A THESIS SUBMITTED 
 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF MECHANICAL ENGINEERING 
















There are many people who have helped me during my study, and this work would 
not finish without their contributions. First of all, I would like to express my deep 
gratitude to my supervisor Dr. Chui Chee Kong and Prof. Hong Geok Soon for their 
guidance and help on my research. They made a deep impression on me for their 
experience, the generous share with me and their dedication to the scientific research. It is 
my great honor to pursue PhD degree under their supervision. 
I would like to thank Dr. Chang K.Y. Stephen from the Department of Surgery, 
National University Hospital and Dr. Eric Khoo from Department of Medicine, National 
University of Singapore for their helpful suggestions and kind help. I appreciate the help 
from MS. Wang Xiaoyan for organizing the clinical data of diabetic patients.  
Thanks for my lab-mates: Wu Yue, Wu Jiayun and Bai Fengjun for their support 
and encourage during my study in NUS. Thanks for my colleagues Ho Yick Wai and 
Nguyen Phu Binh for their suggestions for my research. I wish to thank all my friends in 
Singapore for their help and company. I would like to thank my parents and brother for 
their encouragement and support.  
It is my honor to study in the Department of Mechanical Engineering, National 
University of Singapore. The financial support of National University of Singapore is 
gratefully acknowledged. 









Table of Contents 
 
DECLARATION ................................................................................................................. I 
ACKNOWLEDGEMENT .................................................................................................. II 
Table of Contents .............................................................................................................. III 
Summary ........................................................................................................................... VI 
List of Tables .................................................................................................................. VIII 
List of Figures ................................................................................................................... IX 
List of Abbreviations ..................................................................................................... XIV 
1  Introduction ..................................................................................................................... 1 
1.1 Diabetes Mellitus ....................................................................................................... 1 
1.2 Closed-Loop Insulin Delivery System ...................................................................... 3 
1.2.1 Types of Closed-Loop Insulin Delivery System ................................................ 3 
1.2.2 Prototypes of Closed-Loop Insulin Delivery System in Market ........................ 4 
1.3 Motivation and Scopes .............................................................................................. 6 
1.4 Thesis Organization ................................................................................................... 8 
2  Review of Virtual Patient Models ................................................................................ 10 
2.1 Bergman Minimal Model ........................................................................................ 14 
2.2 Sturis Model ............................................................................................................ 17 
2.3 Hovorka Model ........................................................................................................ 19 
2.4 Summary .................................................................................................................. 22 
3  Model of Glucose – Insulin System with Delays ......................................................... 23 
3.1 Periodic Oscillation of Insulin ................................................................................. 23 
3.1.1 Rapid Oscillation .............................................................................................. 24 
3.1.2 Ultradian Oscillation ........................................................................................ 25 
3.2 Models of Ultradian Oscillation of Glucose-Insulin System .................................. 28 
3.3 Modeling Glucose-Insulin  System with Two Explicit Delays ............................... 32 
3.3.1 Structure of Glucose-Insulin Model ................................................................. 32 
3.3.2 Glucose Dynamics of the Two-compartment Model ....................................... 36 
3.3.3 Insulin Dynamics of the Two-compartment Model ......................................... 39 
IV 
 
3.4 Physiological Analysis of the Model Parameters Effect on the Oscillatory Behavior 
of the System ................................................................................................................. 41 
3.4.1 Insulin Transfer Rate Constants m1 .................................................................. 42 
3.4.2 Insulin Transfer Rate m2 ................................................................................... 43 
3.4.3 Plasma Insulin Degradation Rate m3 ................................................................ 44 
3.4.4 ISF Insulin Clearance Rate m4 .......................................................................... 45 
3.4.5 HGP Delay τ1.................................................................................................... 46 
3.4.6 Insulin Secretion Delay τ2 ................................................................................ 47 
3.4.7 Combined Effect of the Two Delays ................................................................ 48 
3.4.8 Glucose Infusion Rate Gin ................................................................................ 50 
3.4.9 Discussion ......................................................................................................... 51 
3.5 Summary .................................................................................................................. 57 
4 Model of Glucose-Insulin System with Subcutaneously-Injected Insulin ..................... 59 
4.1 Introduction ............................................................................................................. 59 
4.2 Models of Subcutaneous Insulin ............................................................................. 62 
4.2.1 Compartmental Models .................................................................................... 63 
4.2.2 Non-Compartmental Models ............................................................................ 69 
4.3 Modeling Glucose-Insulin System with Subcutaneously-Injected Insulin ............. 72 
4.3.1 Model of Glucose and Insulin Subsystems ....................................................... 72 
4.3.2  Models of Meal ................................................................................................ 75 
4.4 Clinical Evaluation of Model with Subcutaneously-Injected Insulin ...................... 79 
4.4.1 Material ............................................................................................................ 79 
4.4.2 Methods ............................................................................................................ 80 
4.4.3 Results and Discussion ..................................................................................... 83 
4.5 Summary ................................................................................................................. 92 
5 Glucose Control Using Model Predictive Controller..................................................... 96 
5.1 Model Predictive Control ........................................................................................ 96 
5.2 Glucose Control using Two-compartment Model and Minimal Model .................. 99 
5.3 Glucose Control with Injected Insulin ................................................................... 109 
5.4 Summary ................................................................................................................ 119 
6 Conclusion and Future Work ..................................................................................... 122 
V 
 
6.1 Conclusion ............................................................................................................. 122 
6.2 Future Work ........................................................................................................... 125 
6.2.1 Model Improvement ....................................................................................... 125 
6.2.2 Abnormalities of Ultradian Oscillations ......................................................... 127 







With development of insulin, blood glucose meters and insulin delivery devices, 
automatic regulation of glucose level is feasible. Closed-loop insulin delivery system 
(also known as an artificial pancreas) could potentially be the ultimate solution for blood 
glucose control in diabetic patients. Three indispensable factors of a blood glucose 
regulation device are: glucose sensor for measuring glucose concentration, control 
algorithm regulating external insulin infusion, and insulin infusion device. With good 
knowledge of the physiology of blood glucose regulation, an accurate glucose-insulin 
interaction model and a safe, efficient glucose control algorithm could be developed.  
Many researchers have proposed models of human glucose-insulin system to match 
predicted mechanism of endocrine system and investigate the underlying causes of 
diabetes. Optimal glucose control can be achieved by subcutaneous insulin delivery after 
subcutaneous glucose measurement. It is crucial to investigate dynamics of glucose and 
insulin in the subcutis. A new two-compartmental model with two explicit delays on 
hepatic glucose production and insulin secretion was applied to investigate the oscillatory 
behavior of glucose-insulin system when there is no external insulin delivery. Four 
parameters in insulin system and two delays were analyzed for their influence on glucose-
insulin system; their ranges were estimated for sustaining the oscillations and discussed. 
Effect of these parameters on the lag between glucose and insulin in different 
compartments provide insights on distribution and metabolism of glucose and insulin in 
different compartments. Physiological delay has been demonstrated to be an important 
issue for effective blood glucose regulation. 
Local degradation and time delay of transportation and absorption should be 
considered in the insulin module of the glucose-insulin system if exogenous insulin is 
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injected in the subcutaneous tissues. Based on the two-compartmental model, a modified 
model, including two absorption channels and local insulin degradation, was proposed to 
simulate glucose-insulin system with external insulin delivery. Two rate parameters 
expressing insulin transportation from subcutis to plasma compartment, two delays and 
two parameters expressing the dysfunction of diabetic patients were adjustable and 
estimated using nonlinear least squares method. Clinical data comprising glucose level, 
insulin injection dosage and meals was collected from diabetic inpatients. By comparing 
fitting results with existing model, the proposed model can mimic the dynamics of 
glucose and insulin. The estimated model parameters were physiologically meaningful, 
and provided insights on the subject’s dysfunction due to diabetes. 
The goal of a model predictive control (MPC) is to minimize an objective function 
by selecting optimal input moves. MPC has been used in glucose level regulation. Insulin 
dosage calculated by the MPC controller is the input to the plant (i.e., human body). 
Glucose level was output and feed to MPC controller. Two MPC controllers using the 
two-compartment model and the model including the dynamics of subcutaneous insulin 
were investigated, and results of glucose control were compared with that of Bergman 
minimal model and Hovorka model, respectively. MPC controllers using our models 
were demonstrated to be able to reduce occurrence of hypoglycemia and hyperglycemia, 
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1  Introduction 
1.1 Diabetes Mellitus 
Diabetes Mellitus is a common disease around the world, which can induce various 
systemic diseases and high mortality. The World Health Organization estimates that there 
are more than 180 million people suffering from diabetes, and the number may double by 
2030. Diabetes can be catalogued into Type 1 and Type 2 diabetes. Type 1 diabetes, often 
occurring among children and young, makes up 5% to 10% of diabetes cases, and is 
characterized as inability of producing any insulin by their bodies. While Type 2 diabetes, 
usually developing in middle aged or later, is associated with high insulin resistance, 
which results in unused glucose cumulating in body to cause hyperglycemia and tissue 
damage over time . 
High blood glucose level can cause high osmotic pressure in the extracellular fluid 
resulting in considerable cellular dehydration. Secondly, high level of glucose would 
cause glucose loss in the urine, which is followed by osmotic dieresis depleting fluids and 
electrolytes of the body. Besides, long-term high blood glucose can damage many tissues, 
especially blood vessels. Low glucose concentration below 45-55 mg/dL for a long 
interval may bring about brain function impairment, tremors and convulsions. An 
intensive insulin therapy can reduce the risk of complications resulted from diabetes. 
Hyperglycemia can be minimized and hypoglycemia can be avoided by proper insulin 
delivery. 
The conventional therapy of diabetes is multiple subcutaneous insulin injections 
using long or short acting insulin analogues after glucose level measurement by glucose 
monitor. Insulin pen devices can make insulin delivery more convenient. There are some 
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other routes of insulin delivery such as inhaled insulin, orally administered insulin, 
transdermal insulin delivery and so on. Continuous subcutaneous insulin infusion using 
external insulin pump has been applied to regulate blood glucose concentration. In the 
past decades, some continuous or semi-continuous glucose monitors and insulin infusion 
pumps have received approval, both of which promote the development of closed-loop 
insulin delivery system. A closed-loop insulin delivery system relying on a continuous 
glucose sensor, insulin infusion pump and an advanced control algorithm can be 
developed to control blood glucose concentration automatically. 
The control algorithm can optimize insulin dose to be delivered to the patient by 
insulin pump in order to maintain glucose concentration within the normal range. 
Proportional-integral-derivative (PID) method to control blood glucose level has attracted 
interests of many researchers [4-7]. Difference between measured glucose level and 
reference value multiplied by proportional constant, integrated over a period of time, and 
its derivative are used to control the insulin input. Although the simple control approach 
is easy to implement, it cannot provide insight into the physiological meaning of the 
metabolic system, and human expertise is needed to ensure the successful operation, 
which restricts greatly the functioning of this approach. Due to the complexity of 
nonlinear dynamics of glucose-insulin metabolic system, model predictive control (MPC) 
taking advantage of detailed process models and information regarding process 
constraints or limitations is more advantageous in regulating blood glucose concentration. 
Advanced control algorithm is one of the three important factors developing closed-loop 




1.2 Closed-Loop Insulin Delivery System 
The closed-loop insulin delivery system, which is also called artificial pancreas, is 
composed of three essential components: a stable glucose sensor for measuring the 
glucose concentration, a control system regulating external insulin infusion based on the 
glucose-insulin system and a safe and stable insulin infusion device [1].  
 
1.2.1 Types of Closed-Loop Insulin Delivery System 
There are two ways to divide the closed-loop insulin delivery system: way of 
prandial insulin delivery and the body interface. Glucose excursion by meals is a great 
challenge to closed-loop insulin delivery system. In a closed-loop insulin delivery system, 
insulin is delivered fully automatically without knowledge of exercise or meals’ time, 
size or composites, and it is only based on the evaluation and prediction of the measured 
glucose level. In a closed-loop insulin delivery system with meal announcement, the 
system is informed of the time and size of the meals and gives out advised prandial 
insulin bolus to deliver [2]. There is also a hybrid approach which delivers up to 50% of 
bolus insulin and leaves the remaining to be delivered during the feedback.  
There are three types of closed-loop insulin delivery system according to the body 
interface: sc-sc system (subcutaneous glucose sensing and subcutaneous insulin delivery), 
iv-ip system (intravenous glucose sensing and intraperitoneal insulin delivery), and iv-iv 
system (intravenous glucose sensing and intravenous insulin delivery). Insulin delivery 
via subcutaneous route has advantages over intravenous or intraperitoneal route: low 
incidence of infection, less pain and discomfort and ease of administration.  The sc-sc 
system is easy and safe to implement though it results in insulin absorption delay. The iv-
iv system is usable under some situations such as surgical operations, for critically ill and 
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research investigation. However, this approach is high invasiveness due to the need of 
vascular access for the glucose sensing and insulin delivery. Up to now, there are a few 
prototypes developed and tested under limiting clinical conditions. 
 
1.2.2 Prototypes of Closed-Loop Insulin Delivery System in Market 
Median relative absolute difference (MRAD) is often used to evaluate the 
performance of the continuous glucose monitoring (CGM). Freestyle Navigator CGM 
(Abbott Diabetes Care, Alameda, CA, US) is reported to achieve an average MRAD of 
14% [2]. Continuous Glucose Monitoring System (CGMS, Medtronic Minimed, 
Northridge, CA, US) [3] is reported with slightly higher MRAD than Freestyle Navigator 
CGM, and DexCom Seven STS [4] with an MRAD of 11.4%. The three CGMs can be 
used for 3, 5, and 7 days in a closed-loop insulin delivery system, respectively.  
The earliest closed-loop insulin delivery system was the Biostator, Glucose-
Controlled Insulin Infusion System, introduced in 1977, which was an iv-iv system using 
a glucose oxidase sensor to measure the glucose level in the blood and peristaltic pump to 
deliver insulin and glucose intravenously. The control algorithm of Biostator is 
oversimplified. After Biostator, Shichiri’s group developed a wearable artificial pancreas 
named STG-22 (Nikkiso Co. Ltd., Japan) [5] using the sc-sc route and sc-ip route, and the 
microdialysis type glucose sensor in the system can work up to 7 days. 
Medtronic Minimed developed an external physiologic insulin delivery [6] 
employing the CGMS (Medtronic Minimed, Northridge, CA, US) and the Medtronic 511 
Paradigm Pump with a PID controller [7]. Studies using the system is performed on dogs 
[8] and  10 subjects with Type 1 diabetes [6]. Glucose level keeps in the range 3.9-10 
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mmol/L 75% of the time applying closed-loop treatment, compared with that of 63% for 
open-loop treatment. 
Roche Diagnostics developed a sc-sc semi-closed-loop prototype with meal 
announcement employing subcutaneous continuous glucose monitor (SCGM1, Roche 
Diagnostics GmbH, Germany) which can monitor glucose level for 4-5 days [9]. Insulin 
bolus was administrated every 10 min, which is determined by an “empirical algorithm” 
based on clinical observations. The system was tested on twelve Type 1 diabetic subjects 
over 32 hours. It was shown that the algorithm can reach near-target glucose level and 
reduce the number of hypoglycemia interventions. 60% of SCGM1 readings were in the 
range 5-8.3 mmol/L compared to that of 45% under self-directed treatment. An European 
Commission funded project Advanced Insulin Infusion using a Control Loop [10] also 
developed a sc-sc semi-closed-loop with meal announcement, which is composed of a 
minimally invasive glucose monitor system, an insulin pump (Disetronic D-Tron) and a 
PocketPC computer. An adaptive nonlinear MPC is applied in the system.  
The Renard group developed an implantable insulin delivery system employing a 
long-term sensor system [11, 12] which is an intravenous enzymatic oxygen-based sensor 
by Medtronic Minimed (Northridge, CA, US) implantable in the superior vena cava. The 
pump, implementing Proportional-derivative (PD) control, is implanted in the abdominal 
wall and delivers insulin intraperitoneally. The system implemented test on four elderly 
Type 1 diabetes subjects over 2 days and for 84.1% time glucose level is in the range of 
4.4-13.3 mmol/L [1].  
The sc-sc system will gain wide applications in the near future due to its safety and 
convenience to implement and maintain. However, there are two physiological factors 
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affecting the performance of a sc-sc system. One is the delay between insulin delivery 
and sensed glucose lowering. It would take some time for the glucose level to go down 
after the insulin delivery; therefore, subjects using insulin pumps should be alerted insulin 
overdosing due to insulin administrations in a close sequence, which is followed by 
hypoglycemia. The other factor is the inter-subject variability of insulin delivery. 
Actually, developing a “one size fits all” closed-loop system is difficult due to some 
factors such as age, gender, body mass index, physical exercise or some other diseases. 
For the same person, insulin needs are different day-to-day or even hour-to-hour because 
of some physiological or physical reasons. The problem of insulin absorption delay can 
be solved by including the delay in the model of glucose-insulin metabolic system. The 
second factor causes problem for all the closed-loop insulin delivery systems, which is 
expected to be improved by advanced control algorithm such as MPC. 
 
1.3 Motivation and Scopes 
Subcutaneous glucose monitoring and insulin delivery is advantageous over the 
other two approaches for closed-loop insulin delivery system. Therefore, subcutaneous 
tissue is to become the main measurement site of glucose sensor and administration sit of 
exogenous insulin. It is therefore important to understand the kinetics interactions of 
glucose and insulin between plasma and subcutaneous tissues.      
The timing and amplitude difference of plasma glucose and glucose in interstitial 
fluid (ISF) may reflect the variation of glucose uptake, utilization and elimination in 
blood, ISF and cells [13]. Besides, the lag and amplitude difference are also 
characteristics of insulin kinetics between plasma and ISF. However, in most current 
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studies, glucose [14-18] and insulin [15, 18] are considered as a one-compartment model 
during the study of the physiological processes. The ignorance of the lag and amplitude 
difference of glucose in the two compartments would result in loose control of glucose 
level to cause hyper- or hypoglycemia. Therefore, a new two-compartment model is 
developed to express the glucose and insulin metabolic system.  
The new two-compartment model aims to study the physiological phenomenon and 
pathology in diabetes by analyzing the changes of glucose and insulin level, lags existing 
in the glucose-insulin system and the effect of model parameters on the oscillatory 
behavior of glucose-insulin system. Using the proposed mathematical model, the effect of 
the model parameters on blood glucose regulation is investigated. Some key issues are 
analyzed from the perspective of physiology and pathology: 
• Effect of model parameters on the oscillatory behavior of the glucose-insulin 
system. 
• Pathological relations of parameters’ change with some diseases related to 
abnormal glucose level. 
• Influence of model parameters on the interactions of glucose and insulin between 
plasma and ISF compartment regarding physiological lags and amplitude 
differences. 
The two-compartment model without considering external insulin injection/ 
infusion is developed and analyzed physiologically. For diabetic patients, external insulin 
injected subcutaneously is administered to the two-compartment model to simulate the 
metabolism of glucose and insulin. It is the first model to include the dynamics of 
injected insulin into the glucose-insulin model for type 2 diabetic patients. This model 
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considering the dynamics of injected insulin provides insights on the dynamics of human 
blood glucose regulation, and helps derive control algorithms for treatment of diabetic 
patients. The following points were studied: 
• In order to model insulin absorption delay in the sc-sc insulin delivery system, the 
ISF compartment of insulin in the two-compartment model aforementioned was 
separated into three compartments considering insulin degradation at the injection 
site and two insulin absorption channels.  
• Six model parameters value were estimated by fitting the model with injected 
insulin to clinical data of diabetic patients, and the fitting result of our model is 
compared with that of Hovorka model.  
• The six model parameters were discussed physiologically and pathologically 
considering the situations of the diabetic subjects.  
• MPC controller was investigated using the two-compartment model and the 
modified model with subcutaneous insulin, and compared the control performance 
with that of using Bergman minimal model and Hovorka model, respectively. The 
glucose curves and insulin dosages in the simulations of the models were 
compared accordingly to evaluate the performance of glucose control.  
 
1.4 Thesis Organization 
The aim of this thesis is to study the oscillatory behavior of glucose and insulin and 
assess the feasibility of using the model to control blood glucose concentration for 
diabetic patient. A detailed model of glucose-insulin system is indispensable to achieve 
this. Chapter 2 introduces some established mathematical models of glucose-insulin 
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system. In chapter 3, a two-compartment model was developed and analyzed 
physiologically to investigate the oscillatory behaviors of glucose and insulin. The two-
compartment model was modified to simulate the dynamics of insulin injected 
subcutaneously in Chapter 4. The model parameters in the modified model were 
estimated using the clinical data of diabetic subjects and discussed and related to diabetes. 
MPC controllers were developed in Chapter 5 using the two-compartment model and the 
modified model with injected insulin. The control performance of the two models was 
compared with that of Bergamn minimal model and Hovorka model, respectively. 
Simulation results addressed the challenges in using the current models to design a 
closed-loop insulin delivery system. A discussion on the future modeling of glucose-
insulin system was introduced in Chapter 6. Further investigation of virtual patient model 
is necessary with the growing understanding of diabetes.  
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2  Review of Virtual Patient Models  
Since the development of the concept of “artificial pancreas”, there have been many 
researchers studying on the modeling of glucose-insulin regulation system in order to 
understand the mechanism of endocrine system and causes of diabetes and develop a safe, 
efficient glucose control device to relieve the suffering of the diabetes patients. These 
virtual patient models promote the development of advanced control algorithm to regulate 
glucose concentration and investigation of the pathophysiology of diabetes.  
Most mathematical models of glucose-insulin system are based on the idea of 
compartment. When compartmental model is applied to describe the metabolic system 
composed of a series of interconnected compartments, there are several specifications 
needed to be illustrated: compartment number, input and removal sites, and mathematical 
relations of interdependences and controls [19].   
The glucose-insulin regulatory system is a complex system controlled by many 
cerebral signals and hormones; up to now, there has not been a model which can express 
all the interactions of glucose and insulin in the human body. Even, there is much 
physiological phenomenon in human being body which still cannot be explained by 
researchers. Some models developed during the last few decades are introduced in this 
chapter. The advantages and shortcomings of the glucose-insulin models are reviewed in 
[20-22]. 
Virtual patient models can be catalogued into two groups. One is the 
pharmacokinetic (PK) model, in which absorption and clearance kinetics are expressed, 
and some compartments are determined related to the elimination and absorption. The 
other type is the physiological models in which organ system is considered as a 
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compartment, and mass balance of each organ is written by considering convection due to 
metabolic processes, and diffusion between blood and organ cells. The PK models are 
easier to identify from experimental data compared with the second type. 
The early PK model developed by Bolie consisted of one linear equation for insulin 
and one for glucose [23]. First order rate equations were used to express absorption and 
elimination kinetics. This model was modified by Ackerman et al. [24] by involving 
insulin and other hormones in glucose regulation together as a single variable. The 
glucose regulatory system is still oversimplified due to the fact that insulin or hormone 
secretion is more complex than a first order process.  
A two-compartment model for insulin in normal and diabetic patients was 
developed by Frost et al. [25]. Insulin secretion rate was considered as an exponential 
function of glucose for normal subjects and zero for diabetic subjects. Insulin elimination 
was expressed by a nonlinear saturation function of insulin for normal subjects and a first 
order process for diabetic subjects.  
A three-compartment model was proposed by Sherwin et al. [26] in which a central 
compartment exchanged insulin continuously with other two compartments. Insulin 
appearance and elimination from each compartment were modeled as first order kinetics. 
Another three-compartment model developed by Cerasi [27] is similar to Sherwin model. 
It comprised six ordinary differential equations (ODE) to describe physiological insulin 
secretion. The three-compartment model proposed by Insel et al. [28] included one 
nonlinear term to take into account the effect of insulin on glucose uptake.  
A two-compartment model describing glucose and its regulatory hormones was 
developed and validated with data from intravenous glucose tolerance tests (IVGTT) and 
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oral glucose tolerance tests (OGTT) in [29]. A nonlinear model of free fatty acid glucose 
metabolism was proposed for normal subjects in [30]. The system, consisting of 15 states, 
36 metabolic equations and 22 parameters, comprised of glucose, insulin, epinephrine, 
glucagon, growth hormone and free fatty acid models.  
A new model of glucose-insulin system in normal humans was present to describe 
the physiological events occurring after a meal in [31]. The glucose-insulin system 
consisting of 12 states was decomposed into glucose and insulin subsystem both 
expressed by two compartments. 35 model parameters were estimated for normal and 
Type 2 diabetic patients by fitting the mean data of normal subject database undergoing a 
triple tracer meal protocol. 
The Automated Insulin Dosage Advisor on the website (http://www.2aida.net/) is a 
three-compartment model expressing glucose and insulin dynamics. The insulin 
dynamics in the model was driven by subcutaneous insulin injection. The model, 
proposed as an educational tool, was originally designed to study the use of different 
insulin analogues on the insulin therapy and the effect of different meal sizes on the rate 
of gastric emptying in the system.  
The second type of virtual patient models describes biochemical dynamics at each 
important organ site. The organs with significant appearance or clearance of glucose and 
insulin are selected as main compartments. Foster et al. [32] proposed one model of this 
type assuming glucose compartment for blood, muscle and liver, and assuming a 
compartment each for insulin, glucagon and fatty acid. Guyton et al. modified Foster 
model by adding a central organs compartment to the glucose model, including diffusion 
in the transport equations, and making insulin secretion more complex [33].  
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Sorensen [20] divided the central organs compartment into brain and gut 
compartment and included the effect of glucagon. This model consisted of six-
compartment: brain, heart and lungs, liver, gut, kidney and peripheral tissues. The 
dynamics in the ISF and capillary fluid were detailed in the compartment of brain and 
peripheral tissues. Glucose meal disturbance was directly input into the gut along with the 
intravenous delivery of insulin and arterial blood glucose measurement. The model 
consisting of 21 states and 22 metabolic functions described the dynamics of glucose, 
insulin and glucagon. Puckett [34] proposed a new model similar to Sorensen model, 
however it did not include glucagon and removed transport terms besides metabolic sinks 
and sources.  
A kinetic model of glucose regulation system was developed and validated in [35] 
with 6 parameters to identify. The four states in this model expressed the insulin and 
glucose concentration, overall endogenous glucose balance and the peripheral insulin-
dependent glucose utilization (IDGU).  
Cobelli et al. [14] proposed a nonlinear model consisting of glucose, insulin and 
glucagon subsystems. There were 9 states, 23 metabolic functions and 46 parameters in 
this model. Glucose and glucagon subsystem were modeled using a single compartment 
respectively, and insulin subsystem was expressed as a five-compartment model. There 
were 7 ODEs and 23 metabolic functions to describe the glucose-insulin-glucagon system. 
Although Sorensen’s model is widely used in glucose control, it has also been 
criticized for not accurately representing observed glucose change [22]. In addition, 
model parameters must be estimated accurately to ensure the simulation results. However, 
the accuracy of physiological model is lowered due to the large numbers of model 
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parameters compared with PK models. Model parameters are estimated by comparing 
simulation responses with glucose and insulin data, and selecting the parameter set that 
has the minimal sum of squared residuals. Therefore, lower order models can be 
estimated with a single set of glucose or insulin data, which is an advantage over larger 
models. 
Three virtual patient models will be highlighted in the following sections. The 
Bergman, Sturis and Hovorka models are all PK models and used in following chapters. 
All the three models have some common limitations although the structures of the models 
are different: 
1. The counter-regulatory hormones (e.g., glucagon, epinephrine, etc.) have 
profound effect on the change of glucose and insulin. The effect of these 
hormones in the body is not taken into account in the models. 
2. Some physiological factors such as stress or sickness can greatly affect the 
dynamics of glucose and insulin in the human body.  
3. Exercise or some other physical activities can affect the metabolism of glucose 
significantly, which further compound the modeling of glucose-insulin system. 
This factor is ignored in the three models. 
4. The models do not consider the variations in the absorption of different foods. 
 
2.1 Bergman Minimal Model 
Minimal model suggested by Bergman et al [36] with low-order was for estimation 
of insulin sensitivity and glucose effectiveness. It is widely applied in clinical studies and 
mathematical modeling of glucoregulation studies. A revised model was developed by 
Cobelli et al. [37] to estimate glucose clearance and insulin sensitivity. Minimal model 
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was improved in [38] to represent glucose subsystem using two compartments. Hovorka 
et al. [39] added three glucose and insulin subcompartments to extend the original 
minimal model.  Some other modified models are proposed as well [40, 41]. Most models 
were glucocentric and ignored the effect of free fatty acid (FFA). Roy et al. [42] extended 
the Bergman minimal model by including plasma FFA dynamics focusing on Type 1 
diabetic patients.  
A schematic of the Bergman minimal model is shown in Figure 2.1. The minimal 
model, compatible with some known physiological facts, can simulate the glucose-insulin 
system with minimal identifiable parameters and is computationally suitable for 
parameter estimation and real-time control. 
                            
Figure 2.1. Block diagram of the minimal model. The solid arrows represent material flow, the 
dashed arrows imply the interactions between compartments, and the dotted arrow presents the 
effect of plasma insulin on the remote compartment. 
 
As shown in Figure 2.1, Bergman’s minimal model consists of a glucose 
compartment G, a remote insulin compartment X and an plasma insulin compartment I. 
Glucose uptake is influenced by plasma insulin through a remote compartment. The 
model is composed of three differential equations: 
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where G and I are concentration of plasma glucose (mg/dL) and plasma insulin (mU/L), 
respectively. Gb and Ib are the basal levels of plasma glucose and insulin, accordingly. X 
is proportional to the insulin level in the plasma compartment (min-1). It is introduced to 
account for the accelerating glucose disappearance into the periphery and liver, and 
inhibiting hepatic glucose production (HGP).  
Plasma glucose level decays at a rate (p1: min-1) proportional to the difference 
between the plasma glucose level G(t) and the basal glucose level Gb. If the plasma 
glucose level is below the basal glucose level, glucose enters into plasma, and glucose 
leaves plasma if plasma glucose level is above the basal glucose level. The second term, 
−X(t)G(t) describes an additional mechanism via which glucose disappears from plasma 
by the clearance effect of insulin in the remote compartment. D(t) is glucose intake rate 
due to a meal disturbance (mg/min). The change rate of glucose is the difference between 
net hepatic glucose production and the utilization of glucose by the tissues and organs. 
Glucose uptake within glucose space to peripheral and hepatic tissues is mediated by the 
remote insulin compartment. The insulin dynamics of the model is driven by an 
intravenous infusion of insulin to the system.  
Remote-compartment insulin disappears at a rate (p2: min-1) proportional to itself, 
and enters at a rate (p3: min-2 (mU/L)) proportional to the difference between plasma 
insulin level I(t) and basal insulin level Ib. Insulin enters plasma compartment from 
pancreas at the rate of γ [(mU/L)min-1(mg/dL)-1] with glucose level above h (mg/dL) and 
disappears at a rate (n: min-1) proportional to its concentration. u(t) is the exogenous 
insulin infusion rate (mU/min). 
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Though its wide application, a major limitation was reported that glucose 
production cannot separate from its disposal. The indices insulin sensitivity and glucose 
effectiveness describe not only the effect of glucose and insulin on the glucose utilization 
but also the inhibitory effect on the glucose production [43]. Other limitations include 
poor precision of parameter estimation and unsatisfactory reproducibility of the index 
insulin sensitivity. Although these limitations, the model has been validated extensively 
on human patients.  
 
2.2 Sturis Model 
Oscillatory behavior of glucose and insulin in human body has been revealed from 
in vivo and in vitro experiments. Ultradian oscillation of plasma glucose and insulin 
concentration with large amplitude in humans has been observed after meal ingestion, 
oral glucose, constant intravenous glucose infusion and continuous enteral nutrition. A 
three-compartment model including major metabolic processes in glucose regulation was 
proposed to determine whether the oscillations resulted from the feedback loops between 
glucose and insulin [44], as shown in Figure 2.2. Two major negative feedbacks in the 
model, both including the stimulatory effect of glucose on insulin secretion (IS), describe 




Figure 2.2. Flow diagram of Sturis model. Solid arrows represent exchange rate, flows of input 
and output; dashed arrows represent metabolic relationship between compartments. 
 
The model has three main states: amount of glucose in the glucose space, amount of 
plasma insulin and amount of insulin in the ISF. The model equations are shown as 
following: 
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where x (mU) and y (mU) are the insulin amount in plasma and ISF, respectively; and z is 
glucose amount in glucose space (mg). The variables h1, h2 and h3 express the delay 
between plasma insulin and HGP. f1 and f5 denote IS and HGP, respectively. f2 and f3f4 
describe insulin-independent glucose utilization (IIGU) and IDGU, respectively. 
 The metabolic functions are shown in Eq. 2.3; definition and value of model 
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Table 2.1. Definition and value of Sturis model parameters. 
Parameter Definition Value 
E Rate constant for insulin exchange between plasma and remote compartment 0.2 L/min 
I Exogenous glucose delivery rate 216 mg/min 
t1 Time constant for plasma insulin degradation 6 min 
t2 Time constant for remote insulin degradation 100 min 
t3 Delay time between insulin and glucose production 36 min 
V1 Volume of insulin distribution in the plasma 3 L 
V2 Volume of remote insulin compartment 11 L 
V3 Volume of glucose space 10 L 
 
 
2.3 Hovorka Model 
In a similar manner with Bergman model, Hovorka et al. [45] proposed a nonlinear 
model to develop model predictive controller in subjects with Type 1 diabetes. The 
compartment model includes submodels expressing absorption of subcutaneously 
administered short-acting insulin Lispro and gut absorption. The model outline is shown 




Figure 2.3. Compartment model of glucose-insulin system proposed by Hovorka et al.. Solid 
arrows represent exchange rate, flows of input and output; and dashed arrows represent insulin 
action on glucose metabolism. 
 
The model comprises a glucose subsystem (glucose absorption, distribution and 
disposal), an insulin subsystem (insulin absorption, distribution and disposal) and an 
insulin action subsystem (insulin action on glucose transport, disposal and endogenous 
production). The model equations of glucose subsystem are shown by Eq. 2.4: 
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The functions of metabolic processes are shown in Eq. 2.5. The definition of the 
state variables and model parameters are listed in Table 2.2 and Table 2.3, respectively. 
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Table 2.2. Definition of Hovorka model variables. 
Variable Definition Unit 
G Plasma glucose concentration mmol/L 
Q1 Glucose mass in accessible compartment mmol 
Q2 Glucose mass in non-accessible compartment mmol 
F01 Insulin-independent glucose flux mmol/(Lmin) 
FR Renal glucose clearance mmol/(Lmin) 
UG Glucose absorption rate mmol/(Lmin) 
I Plasma insulin concentration mU/L 
x1 Insulin action on glucose transport min-1 
x2 Insulin action on glucose uptake min-1 















Table 2.3. Definition and value of Hovorka model parameters. 
Parameter Definition Value 
k12 
Transfer rate from non-accessible to accessible 
compartment 0.066 min
-1 
ka1 Deactivation rate 0.006 min-1 
ka2 Deactivation rate 0.06 min-1 
ka3 Deactivation rate 0.03 min-1 
kb1 Activation rate 3.07e-5 min-1 
kb2 Activation rate 4.92e-5 min-1 
kb3 Activation rate 1.56e-4 min-1 
ke Insulin elimination rate from plasma 0.138 min-1 
VI Insulin distribution volume 0.12 L/kg 
VG Glucose distribution volume 0.16 L/kg 
DG Amount of carbohydrates digested N.A. 
AG Carbohydrate bioavailability 0.8 
tmax,G Time-to-maximum of carbohydrate absorption 40 min 
EGP0 
Endogenous glucose production extrapolated to zero 
insulin concentration 0.0161 mmol kg
-1  min-1 
F01 Non-insulin-dependent glucose flux 0.0097 mmol kg-1  min-1 
tmax,I 
Time-to-maximum of absorption of subcutaneously 
injected short-acting insulin 55 min 
 
2.4 Summary 
The Bergman, Sturis, and Hovroka models use different approaches to model the 
dynamics of glucose-insulin system. In order to improve the control algorithm of glucose 
regulation and hence the diabetes treatment, virtual patient models have to be refined 
continually for further understanding of the pathology and physiology of diabetes. In 
Chapter 3, a refined two-compartment model based on the Sturis model is proposed to 
explore the oscillatory behavior of glucose-insulin system and the relation of the 
oscillations and diabetes.  
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3  Model of Glucose – Insulin System with Delays  
    Researchers have studied the oscillatory behavior of the insulin, glucose and 
other hormones for decades. Two delays are suggested to be relevant to the oscillations of 
glucose and insulin as well as some lags existing to affect the regulation of glucose 
concentration. Hepatic glucose production delay and insulin secretion delay are two 
delays studied mostly by the researchers. Some lags are observed such as the lags 
between plasma glucose and glucose in the ISF, between plasma glucose and plasma 
insulin, between plasma insulin and ISF insulin, and between IDGU and ISF insulin. 
Glucose level is regulated by these variables and four negative feedback loops among 
them (refer to Figure 2.A in [44]). Insulin action delay and the feedback loop in the 
glucose-insulin system may be key factors of stimulating the oscillations [15, 44]. 
 
3.1 Periodic Oscillation of Insulin 
Periodic oscillation is one of the most significant characteristics of insulin secretion. 
It can pulsate at different amplitudes and periodicities (Figure 3.1) [44]. Oscillation of 





Figure 3.1. Different amplitudes and periodicities of insulin and glucose for different glucose 
infusion rates: (A) meal ingestion; (B) oral glucose intake; (C) continuous enteral nutrition; (D) 
constant glucose infusion. 
 
3.1.1 Rapid Oscillation 
The rapid oscillations of insulin, plasma glucose and glucagon concentration have 
been observed in overnight fasting monkeys [46]. A mean period of 9 min for the insulin, 
plasma glucose and glucagon was proposed. Larger amplitudes for insulin and glucagon 
were reported to be ten and five times greater than glucose.  
    Concurrent oscillations of glucose and insulin was reported with averaging 
period of 13 min in normal men in [47]. Plasma was sampled from ten normal subjects 
every two minutes between one and two hours in this study. In five subjects with regular 
cycle of basal plasma insulin, the average concentration of plasma glucose led plasma 
insulin for 2 min. For the less regular subjects, a two-minute lead of plasma glucose to 
rise before the insulin rise was demonstrated. It was proposed that negative feedback loop 




In order to examine whether the hormone cycles could be sustained without the 
influences of liver or central nerves, isolated canine pancreas was perfused in vitro [48]. 
Sustained regular cycles of insulin secretion, glucagon and somatostatin were observed 
for over 200 min under constant infusion of glucose. The average periods for insulin, 
glucagon and somatostain were 10 min, 8.6 min and 10 min, respectively. Based on the 
experiments results, there might be a pacemaker or a driving oscillator of hormone 
secretion within the pancreas to produce the in-vitro cycles.  
Pancreas was suggested to be possibly a driver or Zeitgeber of the glucose-insulin 
interaction system [48, 49]. The results of in vivo and in vitro experiments were 
compared to study the causes of the oscillations [50]. Samples were taken every minute 
from the portal vein of the dog and from the isolated perfused pancreas in vitro. The data 
from the experiments was in agreement with the proposal in [48] supporting that there 
was a pacemaker within the pancreas to regulate the insulin secretion. The amplitude of 
the oscillation was suggested to be mediated by vagal nerves as well [50].  
 
3.1.2 Ultradian Oscillation 
Ultradian oscillation is regarded as characteristic of intact organism and may be 
inherent to the glucose-insulin feedback system. Some studies on oscillatory behavior of 








Table 3.1. Studies on the oscillatory behavior of glucose-insulin system. 
Source  Subject  Glucose entrance  
Kraegen et al., [51]  Normal man  Oral glucose administration  
Segre et al., [52] Normal, diabetic, obese man  Constant glucose infusion  
Ookhtens et al., [53] Conscious dog  Constant glucose infusion  
Bowden et al., [54] Conscious dog  Constant glucose infusion  
Simon et al., [55] Normal man  Meals  
Simon et al., [56] Normal man Continuous enteral nutrition 
Polonsky et al., [57] Normal & diabetic man Meals 
Sturis et al., [58] Type 2 diabetic, obese, normal man  Fasting  
 
 
Ultradian oscillation is the slower pulsatility of insulin, glucose and some other 
hormones with longer period. The periodic fluctuations of insulin and glucose 
concentration were observed in the arterial plasma of the conscious fasting dogs [53]. The 
measurement of glucose and insulin concentration was taken at frequent regular intervals. 
The observation period varied from 30 minutes to 10 hours and was divided into 64 even 
time sections. It was found that the sustained oscillations of insulin and glucose level 
were observable under constant intravenous glucose infusion.  
A similar experiment was carried on conscious, intact dogs [54]. The oscillations of 
insulin and glucose in the plasma were observed with constant glucose infusion of 10 
mg/kg/min. The glucose level went into regular oscillation after about 3 hours since the 
beginning of the glucose infusion until the end of it. The glucose and insulin 
concentration oscillated with frequencies of 0.54±0.03 cycles/h and 0.6±0.09 cycles/h 
respectively, which were quite close. A lead of glucose before insulin oscillation was 
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observed for 22±5 min. Peripheral glucose utilization was studied as well in this study. It 
proposed that the glucose fluctuation was due to the large fluctuation in peripheral 
glucose utilization; and glucose was the main factor for the hepatic glucose uptake during 
the glucose infusion and insulin for the peripheral glucose utilization. 
Except the constant glucose infusion, meals and constant enteral glucose infusions 
can stimulate the oscillation of glucose and insulin in human body [55, 56]. Eight normal 
subjects were studied for the time profiles of glucose and insulin after three meals in [55]. 
The mean period of the synchronous oscillations of glucose and insulin was about 51-112 
min. The amplitude of the oscillation reached peaks after meals, decreased with time and 
returned to its fasting levels after about 340 min. Rapid oscillations of glucose and insulin 
were observed to superimpose on the ultradian oscillation with different periods of 20-30 
and 9-14 min. The influence of continuous enteral nutrition on the plasma glucose, 
insulin and C-peptide was studied in [56]. The period of the ultradian oscillation and the 
rapid oscillation for plasma glucose and insulin was 53-113 min and 8-14 min 
respectively. A rapid and small-amplitude insulin oscillation of 8-15 min was observed in 
experiments on animals and a slow and large-amplitude oscillation of insulin on human 
every 100-150 min [59]. 
The pulsatility of insulin in 24 hours was studied under 3 mixed meals on 14 
normal subjects and 15 obese subjects [57]. By using a two-compartment kinetics model 
of peripheral C-peptide, insulin secretion rate was derived from the concentration of C-
peptide in the plasma. In the normal subjects, about 11.1±0.5 pulses were observed 
during 24 hours. Obvious pulses of insulin were observable after three meals; and the 
insulin secretion pulsated in the fasting period overnight. For the normal and obese 
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subjects, the number and the time for the insulin secretion pulses was similar, with higher 
amplitudes for the obese subjects. The results suggested that pulse of glucose 
concentration was concomitant with those of insulin especially during postprandial period; 
and the concomitant rate during the fasting period was lower accordingly. 
Sturis et al. investigated the ultradian oscillation of insulin secretion and glucose 
concentration under fasting condition on seven Type 2 diabetes patients, eight obese non-
diabetic subjects and eight normal subjects [58]. Blood was sampled every 15 minutes to 
measure glucose, insulin and C-peptide on the diabetic and obese subjects. For the normal 
subjects, the fasting period was 8 hours. Insulin secretion rate was calculated in the same 
way with [57]. Ultradian oscillation of IS was reported to be evident during the fasting 
period for all the subjects. The rapid oscillation with period of 10-15 min was observed 
using short sampling every 2 minutes. The oscillation frequency was reported to be 
similar for the diabetic and non-diabetic subjects at 12-15 oscillations/24 h; and the 
concomitant rate for the two groups were approaching with mean value of 63%-65%. 
Compared with oscillation of insulin, a slowing of the glucose oscillation in the Type 2 
diabetic subjects was observed.  
 
3.2 Models of Ultradian Oscillation of Glucose-Insulin System 
For better understanding of the endocrine regulatory system and shedding light on 
the oscillatory features of insulin and glucose, many models have been proposed. Some 














No. of glucose 
compartment 
No. of insulin 
compartment Remark 
Sturis et 
al. [44] 0 6 1 2 
3 ODEs without 
physiological 
meaning. 
Tolić et al. 
[17] 0 6 1 2 











3 1 2 
One equation for 
glucose dynamics and 
two for insulin. 
Li et al. 
[15] 2 2 1 1 
Analyzed 4 




Tsai [18] 2 2 1 1 
Two constants 
included to estimate 
the dysfunction due to 
diabetes. 
 
A three-compartment model was proposed by Sturis et al. [44] to study ultradian 
oscillating behavior of glucose and insulin. The model structure is similar to Bergman 
minimal model: a single compartment was used to express glucose subsystem and insulin 
subsystem was modeled using plasma insulin and remote insulin compartment. The 
model of glucose-insulin system consisted of five metabolic functions and six nonlinear 
ODEs, three of which were auxiliary variables without biological meaning to introduce 
the delay of insulin effect on HGP. Tolic et al. [17] simplified the metabolic functions f1-
f5 in Sturis’ model, and two new functions were introduced into the model representing 
the effect of hyperglycemia on HGP and the splanchnic glucose uptake.  
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Engelborghs et al. [61] introduced the delay of HGP explicitly into the model to 
replace the three auxiliary variables based on the study [44], and one-compartment 
insulin model was used. There were only two differential equations instead of six. 
Another delay of glucose effect on IS was not considered in this model, which was 
proved to be unreasonable by Li et al [15]. In their work, they tried to model exogenous 
insulin infusion assuming that the form of exogenous insulin infusion was the same as the 
endogenous insulin secretion. 
Bennett and Gourley [60] introduced the HGP delay explicitly into the model and 
kept the two insulin compartments to express indirectly the delay of IDGU without 
considering delay of IS. The model consisted of three differential equations and was 
analyzed for the sufficient conditions of global stability. 
Li et al. [15] used one-compartment model of glucose and insulin, introduced 
delays of IS and HGP explicitly into the model, and suggested a model expressed by two 
differential equations. Their simulation results indicated that IS delay was important for 
sustaining oscillation of glucose and insulin. The time delay of IS was therefore 
suspected as one of the possibly causes of ultradian oscillation of glucose-insulin system. 
Chen and Tsai [18] followed Li et al. study [15] and included a glucose submodel 
in the glucose-insulin system. There were two differential equations describing the 
glucose and insulin in the plasma compartment. Keeping the five algebraic equations f1-f5 
unchanged, two functions were introduced to express the effect of hyperglycemia. Two 
constants α and β were included in the differential equations to estimate the dysfunction 
condition due to diabetes. There were other mathematical models with delays to express 
glucose-insulin regulatory system, and a review of these models can be found in [62].  
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The role for each delay or both was considered in different way. In [15, 44], the two 
delays were considered separately for their influence on the oscillation behavior of IS and 
HGP. While the two delays’ effect was considered together by using the sum of the two 
delays in [63]. It was proposed that the combined effect of the two delays influenced the 
dynamics of the glucose-insulin feedback mechanism, but not each individual delay. 
Chuedoung et al  [63] concluded that there was a critical composite delay of HGP delay 
and IS delay to affect the oscillatory behavior of the glucose-insulin system. Below this 
critical composite delay, stability can be expected. Li and Kuang [64] suggested that the 
sustained oscillation can occur in the unstable region divided by a curve. So far, there has 
not been any suitable method to conduct experiments to study and ascertain each delay’s 
effect on the endocrine system. The credibility and applicability of the models remains 
largely debatable till further relevant research investigations and findings. In our work, 
the two delays are studied separately followed by combining them to investigate the 
effect on the glucose-insulin system. 
Table 3.3. Range of time delays. 
 HGP delay IS delay 
Sturis et al. [44] 25-50 min N/A 
Prager et al. [65] 0-23.5 min 0-23.5 min 
Engelborghs et al. [61] N/A 50 min(for simulation) 
Li et al. [15] 6.75-40 min  5-15 min 
Wang et al. [66] 15 min(for simulation) N/A 
 
In different studies on the oscillatory behavior of glucose-insulin system, the range 
of IS delay and HGP delay varied widely (Table 3.3). Delay can influence glucose 
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concentration and the lags of glucose and insulin between different compartments to a 
certain extent [66]. Definitions for the delays were not the same in different studies. HGP 
delay was defined as the time taken for the liver to release glucose responding to the 
plasma insulin change in [60, 67]. HGP delay was the time taken for “remote insulin” to 
stimulate HGP to a significant change (e.g. half-maximal) in [15]. IS delay was 
considered as the time from the elevated plasma glucose to the change point of IS in [63, 
67]. In [15], IS delay was measured from the time plasma glucose concentration increases 
to the moment when newly synthesized insulin is transported to interstitial fluid and 
becomes the “remote insulin”.  
3.3  Modeling Glucose-Insulin  System with Two Explicit Delays 
3.3.1 Structure of Glucose-Insulin Model 
The body tissues and organs were divided into two compartments by the different 
rates equilibrating with plasma compartment: slow-equilibrating with plasma and rapid-
equilibrating with plasma compartment in [26, 31]. The organs with large blood flow 
relative to their interstitial volume have a rapid rate of equilibrating (e.g. heart, liver, gut 
and kidney); while other poorly perfused tissues have slow equilibrating rate (e.g. skin, 
muscle and adipose tissues).  
After the insulin is secreted by pancreas and passes liver, it goes into plasma and 
circulates to various human organs. The insulin then transverses the capillary membrane 
and enters the interstitial fluid. Finally, insulin is bound to the cell receptors on the 
membrane of insulin-dependent tissue cells, and the cells ‘open’ to let the glucose in. 
IIGU mainly happens in brain and nerve cells. The permeability of the cells is so high 
that the cells can utilize glucose even without insulin [68]. IDGU often occurs in insulin-
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dependent tissues, such as muscle and adipose tissues, where glucose in the ISF can be 
utilized under the aid of insulin in the ISF. The glucose uptake correlates closely with 
insulin in ISF rather than with plasma insulin [69]. For diabetic patients, due to insulin 
deficiency or insulin resistance, glucose level cannot be controlled within the normal 
range and complications are induced.  
Glucose dynamic system was expressed as a one-compartment model and insulin 
dynamic system expressed as two-compartment model in [44]. In later studies, glucose 
and insulin dynamic systems were mostly expressed as a one-compartment model to 
study glucose-insulin oscillatory behaviors [15, 66, 67]. Optimal control of glucose level 
can be achieved by subcutaneous delivery of insulin after glucose measurement. It is 
crucial to investigate and understand the dynamics of glucose and insulin in the 
subcutaneous tissues for better regulation of blood glucose level. In order to investigate 
the oscillatory behavior of the glucose-insulin system and interactions between quick- 
and slow-equilibrating tissues and organs, we construct a two-compartment model of 
glucose and insulin with explicit introduction of two delays, and modify the functions of 
HGP [16], IS and IDGU. The model structure is shown in Figure 3.2, and the complete 
model is given by equation sets (3.1) and (3.2).  
 
 
Figure 3.2. Diagram of two-compartment model. The solid and dashed arrows represent input, 
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The first compartment, plasma and rapidly equilibrating tissues, is expressed as 
plasma for short; the second compartment, slowly equilibrating tissues, which is also the 
remote compartment [31, 44], is expressed as ISF following the definition in [31]. The 
definition of all the variables and parameters in the model are listed in Table 3.4 and 
Table 3.5. HGP delay, defined in the same way in [60, 67], is the time from the insulin 
appearance in plasma to the moment HGP has significant changes. IS delay is expressed 
as the time difference for plasma glucose effect on IS by pancreas, following the 
definition in [63]. The IS delay is different from that in Li et al. [15] in that IS delay of Li 










Table 3.4. Definition of state variables of the two-compartment model. 
Variable Definition  Unit 
Gp
 






















Gin Glucose intake rate mg/min 
HGP Hepatic glucose production mg/min 
Uii Insulin-independent glucose utilization mg/min 
E Renal excretion mg/min 
Uid Insulin-dependent glucose utilization mg/min 
S Insulin secreted by the pancreas mU/min 
 
 
Table 3.5. Parameters definition and nominal value in the model. 
Parameter Definition Nominal values 
Vgp Plasma glucose distribution volume  8.4 L 
Vgi ISF glucose distribution volume  7  L 
Vip Plasma insulin distribution volume  3.15 L  
Vii Insulin distribution volume in ISF  7 L 
e Exchange rate of insulin between plasma and ISF  0.1361 min-1 
ke1  Glomerular filtration rate   0.0005 min-1 [31] 
ke2  Renal threshold of glucose  339 mg/kg [31] 
k1  Transfer rate from plasma to ISF of glucose   0.065 min-1 [31] 
k2  Transfer rate from ISF to plasma of glucose  0.079 min-1 [31] 
m1  Transfer rate from plasma to ISF of insulin 0.042 min-1 [26, 70] 
m2  Transfer rate from ISF to plasma of insulin 0.02 min-1 [26, 70] 
m3  Plasma insulin degradation rate 0.268 min-1 [26] 
m4  ISF insulin clearance rate 0.03 min-1 [26] 
τ1 HGP delay 20 min 





Table 3.6. Distribution volumes for glucose and insulin in different compartments. 
 Glucose space Insulin in plasma Insulin in ISF 
Sherwin et al. [26] N/A 45±3 mL/kg   95 ± 8 mL/kg  
Cobelli et al. [70] 0.2 L/kg 0.045 L/kg  0.1 L/kg 
Sturis et al. [44] 10 L (7-13 L) 3 L (2-4 L) 11 L (7-15 L) 
Hovorka et al. [45] 0.16 L/kg 0.12 L/kg  
Dalla et al. [31] 0.188 L/kg (normal) 0.149 L/kg (Type 2) 
0.05 L/kg (normal) 
0.04 L/kg (Type 2) N/A 
 
Two state variables are considered in the glucose system: plasma glucose (Gp) and 
ISF glucose (Gi). The state variables in the insulin system are plasma insulin Ip and ISF 
insulin Ii. Their values are converted to mg/dL and μU/ml when we report the simulation 
results. The distribution volumes of glucose and insulin space in some studies are listed in 
Table 3.6. Using the estimation method for the distribution volumes of glucose and 
insulin in [70], Vgp, Vgi, Vip, and Vii are estimated respectively as 12%, 10%, 4.5% and 10% 
of bodyweight [14, 26, 31, 45, 70]. Bodyweight (BW) is assumed to be 70 kg in this 
chapter. 
 
3.3.2 Glucose Dynamics of the Two-compartment Model 
There are two glucose sources in the model: glucose intake Gin from gut and 
glucose production from the liver stimulated by the glucagon. Glucose intake rate is 
variable due to different glucose infusions. Gin(t) can be considered to be constant when 
intravenous glucose infusion is applied. Gin increased toward a maximum value and then 
fell slowly to zero in [18]. More complex models for glucose intake from gut were 
proposed in [71, 72]. 
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HGP increases with decreased plasma insulin concentration. HGP was suggested to 
depend on plasma glucose, liver insulin and plasma glucagon in [14]. Glucagon was 
suggested to be unimportant correlations with the oscillatory behavior of insulin and 
glucose in [44]. With a wide range of HGP delay, oscillations of glucose and insulin were 
observable with HGP delay changing from 4.5 to 36 min in [15]. A range of 0-50 min for 
HGP delay is applicable according to Table 3.3. HGP decreases with the increase of 
plasma insulin, shown in Figure 3.3. 
 
Figure 3.3. Change of HGP with plasma insulin level. 
 
Glucose utilization was revealed to be dependent on plasma glucose and insulin 
concentration [14, 44]. It can be divided into insulin-dependent and insulin-independent 
utilization. There are different functions expressing IIGU. It followed Michaelis-Menten 
kinetics form in [73]. While IIGU was in the form of two hyperbolic-tangent functions’ 
product in [14], relevant to plasma glucose and ISF insulin. In [44], IIGU relevant to 





Figure 3.4. Effect of plasma glucose level on IIGU. 
 
IDGU followed the Michaelis-Menten form in [31].  IDGU depended on the plasma 
glucose and ISF insulin suggested in [14, 16, 44], with the mathematical functions 
different. Glucose uptake by the peripheral tissues occurs in the ISF compartment, 
making IDGU a function of ISF glucose concentration [31]. We therefore modified 
IDGU to be a function relevant to glucose and insulin concentration in the ISF 
compartment. The relationship of glucose and insulin in the ISF compartment with IDGU 
was shown in Figure 3.5. 
 
 
Figure 3.5. Change of IDGU with ISF glucose level when ISF insulin is constant at 6 μU/mL (A), 





There was no glucose renal excretion in the model in [44, 60]. However, it is an 
important part in the regulatory system of glucose and insulin. The mathematical model 
of glucose renal excretion was adapted from [31]. Glucose eliminated by the kidney 
occurs when the plasma glucose level is higher than the threshold value and is assumed to 
be linear with plasma glucose. Threshold value of plasma glucose concentration is 
different for different subjects. Threshold value in [31] was therefore used in this chapter. 
 
3.3.3 Insulin Dynamics of the Two-compartment Model 
Basal plasma insulin was about 5-10 μU/ml after an overnight fasting in [74]. A 
mean value of 11.5 μU/ml was measured for the fasting arterial insulin level [26]. Insulin 
equilibration between plasma and ISF was governed by the insulin concentration 
difference in the two compartments [44].  
Insulin is secreted by pancreatic beta-cells when stimulated by elevated plasma 
glucose concentration. Insulin has an inhibitory effect on the HGP and enhances glucose 
utilization by the tissue cells. In our work, the function of IS rate from [44] is modified 
following that in [16]. As shown in Figure 3.6, insulin secretion rate increased slowly 
first, followed by fast climbing from about 150 mg/dL and slowed down until reached a 




Figure 3.6. Change of insulin secretion rate with plasma glucose level. 
 
There are three main clearance sites for insulin: kidney, liver and peripheral tissues. 
Portal insulin degradation happens mainly at liver, and peripheral insulin at kidney, with 
the insulin left to be removed by other tissues [15]. It was suggested that insulin clearance 
in plasma degrades in a single exponential form, and ISF in a linear form with its 
concentration [75, 76]. The process of newly secreted insulin passing liver would degrade 
insulin or recycle via hepatic artery. Insulin destruction by liver on first passage was 
estimated at 40%-55% [26]. In our work, it was assumed the secreted insulin enters 
directly plasma compartment after its first degradation passage through liver [26]. The 
insulin loss by the liver was considered with irreversible plasma insulin loss as a loss 
directly from plasma, which was expressed by the lumped parameter m3.  
Exchange rate of insulin between plasma and ISF compartment e 
The function of IDGU (Uid)  in the proposed model is different from the original 
function in [44]. We define a parameter m4 to express ISF insulin clearance rate. m4 is 
used to replace 1/ti. The parameter e, which is the rate of exchange between plasma and 
ISF compartments, has a different value with that of the original function. 
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Since insulin exchange between plasma and ISF is proportional to the difference 
between the plasma and ISF compartment, the insulin exchange q in the original function 
was: 
                                                   1 2( )q E x V y V= ∗ − , (3.3) 
where x and y are insulin masses in the plasma and ISF respectively, E is the rate constant 
for exchange of insulin between the two compartments, and V1 and V2 are the respective 
distribution volumes for the plasma insulin and remote insulin compartment as defined in 
[44]. In our model, the insulin exchange is: 
                                                                 1 2 ,p iq m I m I= −  (3.4) 
where Ip and Ii were masses of insulin in plasma and ISF compartment respectively, m1 
and m2 were transfer rates of insulin mass between the two compartments. Assuming that 
the two insulin exchanges are equal, two values of E could be obtained, which is relevant 
with IDGU. The two values are averaged to obtain: 
                                       1 1 2 2 1 2( ) 2 ( ) 2.i p iie mV m V mV m V= + = +  (3.5) 
In our model, V1 is expressed as Vip, and V2 is expressed as Vii. 
 
3.4 Physiological Analysis of the Model Parameters Effect on the 
Oscillatory Behavior of the System  
Taking into account the variance of several parameters under different conditions 
and uncertainty of their effects on the oscillatory behavior, computer simulations were 
performed. Results were analyzed for parameters’ impact on the oscillatory behavior of 
the system, and the physiological implication was discussed.  
42 
 
In our simulation, a parameter’s value was altered with all the other parameters 
remained constant at their nominal values. The correlation of ISF glucose level with 
blood glucose level varied from 0.76 to 0.92 [77]. Blood glucose level within 80-120 
mg/dL was suggested in existing studies as the target of glucose control [78] or 
normoglycemia range [79]. The optimal range of plasma glucose concentration (80 
mg/dL-120 mg/dl) and glucose concentration difference (10%-25%) between the two 
compartments were therefore considered in deciding the optimal range for each parameter. 
For different subjects, the parameters’ value should be different. Parameter range for 
different subjects was discussed based on physiological analysis of simulation results.  
In order to investigate the oscillatory behavior of the glucose-insulin system and 
interactions between quick- and slow-equilibrating tissues and organs, we constructed a 
two-compartmental model of glucose and insulin with explicit introduction of two delays, 
and modified the functions of HGP, IS and IDGU. Based on the simulation results, the 
influence of parameters on the oscillatory behavior and their physiological implication 
was analyzed. From section 4.4.1 to 4.4.7, Gin was external glucose infusion rate constant 
at 108 mg/min. 
 
3.4.1 Insulin Transfer Rate Constants m1  
The parameter m1 is increased from 0 to 0.1. A range of m1 is estimated at 0.02-0.08 
to sustain the oscillation of the system (Figure 3.7.A). The lower and upper limits of 
plasma and ISF glucose are reduced because more insulin distributing to ISF increases 
glucose uptake by the tissues. This agrees with normal phenomenon. Plasma glucose 
level increases further with more insulin transferring to ISF in the range of 0.02-0.03 
(Figure 3.7.B), which may be caused by insulin resistance in the subcutaneous tissues. It 
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is estimated that for Type 2 diabetes, m1 may be in the range of 0.02-0.03. Difference 
between plasma and ISF glucose concentration widened with increasing m1. Within one 
oscillation period, for a certain glucose level, level difference between plasma and ISF is 
different for rising and falling side [13, 80]. Therefore the glucose level difference in 
plasma and ISF changes like a closed curve (Figure 3.7.C). For m1 greater than 0.06, 
glucose concentration difference is higher than 25% (Figure 3.7.C). This may indicate an 
inefficient glucose transfer from plasma to ISF caused by some illness. 
 
Figure 3.7. Phase plane of glucose and insulin in the plasma (A), glucose and insulin level 
distribution (B), and glucose level difference (C) when m1 changes. The triangle indicates glucose 
and insulin in plasma go to a steady state when m1=0.01. The level difference was calculated as 1- 
ISF glucose level/plasma glucose level. 
 
3.4.2 Insulin Transfer Rate m2 
In Figure 3.8, m2 is increased from 0 to 0.06. For m2 out of the range of 0.01-0.04, 
oscillations of insulin and glucose are damped (Figure 3.8.A). An optimal range of m2 is 
estimated at 0.02-0.04. By the simulation result, m2 in the range of 0.01-0.02 may imply 
impaired function of glucose distribution in the body, which is shown by high difference 
of glucose concentration between the two compartments (Figure 3.8.B). For m2 greater 
than 0.04, glucose-insulin system reached steady state quickly, and glucose 




Figure 3.8. Phase plane of glucose and insulin in the plasma (A), and plasma and ISF glucose 
level difference (B) when m2 changes. 
 
3.4.3 Plasma Insulin Degradation Rate m3 
In our model, the loss of newly secreted insulin cleared by the liver was considered 
together with irreversible loss of plasma compartment as loss directly from the plasma 
compartment, expressed as a lumped parameter m3. This degradation is named following 
the nomenclature in [44] as plasma insulin degradation. For the irreversible loss of 
plasma insulin and insulin degradation by the liver, they are assumed to be linear with 
plasma insulin mass with rate estimated at 0.125 and 0.268 respectively [14, 31]. 
When insulin degradation m3 increases, glucose increases, and insulin decreases in 
both compartments. A range of m3 is estimated at 0.1-0.6 for periodic solution of the 
dynamic system (Figure 3.9.A). The optimal range for m3 may be within 0.2-0.3 (Figure 
3.9.B and C). For m3 less than 0.2, glucose concentrations in both compartments vary in 
wide range (Figure 3.9.B). This may be caused by inefficient glucose distribution. With 
m3 increasing from 0.3 to 0.6, plasma glucose increases to almost 140 mg/dL and plasma 
insulin decreases to about 30 μU/mL. The high glucose and insulin level under low 
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glucose infusion may be induced by insulin resistance. m3 in the range of 0.3-0.6 was thus 
estimated for Type 2 diabetics.  
 
 
Figure 3.9. Phase plane of glucose and insulin in the plasma (A), glucose and insulin level 
distribution (B), and glucose level difference (C) when m3 changes. 
 
3.4.4 ISF Insulin Clearance Rate m4 
ISF insulin clearance rate is affected significantly by the subject’s health conditions, 
exercises and other biological factors. A wide range of ISF insulin clearance rate exists, 
such as 0.001-0.07/min in [15], 0.01/ min in [44], 0.194/min for normal people and 
0.269/min for Type 2 diabetic patients [31]. We observed that the oscillation of the 
dynamic system can be sustained in the range of 0-1. In agreement with existing studies, 
a range of m4 is assumed to be 0-0.2. 
From Figure 3.10.B, plasma glucose and glucose level difference are always within 
the optimal range. When m4 increases from 0 to 0.02, insulin and glucose in plasma 
increase, and ISF insulin decreases rapidly. This may be caused by poor distribution of 
insulin from plasma to ISF due to disease. For sub-healthy people, the range of m4 is 
likely to be 0-0.02. The optimal range of m4 is estimated at 0.02-0.05. For m4 greater than 
0.05, ISF insulin level drops very low, while plasma insulin concentration hardly changes 
(Figure 3.10.A). Higher ISF insulin clearance results in wide glucose difference change, 
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and the pattern of glucose difference curves varies greatly with the increase of m4 (Figure 
3.10.B). ISF insulin clearance rate may be relevant with the sensitivity of subcutaneous 
tissues to insulin; thus the value of m4 for Type 2 diabetics is likely to be higher than that 
for normal subjects.  
 
 
Figure 3.10. Plasma glucose and insulin level distribution (A), and plasma and ISF glucose level 
difference (B) when m4 changes. 
 
3.4.5 HGP Delay τ1  
Plasma insulin is relevant with HGP by transporting ‘signal’ to liver to stimulate or 
suppress the transformation between glycogen and glucose. During this process, a delay 
was reported to exist [65]. In Figure 3.11.A, HGP delay increases from 0 to 40 min. The 
oscillations can occur when τ1 is greater than 14 min. When τ1 increases, the amplitudes 
of the four state variables increases, and the range of the glucose concentration difference 
between compartments grows quickly (Figure 3.11.B). The observation indicates that 
glucose fluctuation become more significant with longer delay.  
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An optimal range of τ1 is estimated at 14-22 min. For HGP delay longer than 22 
min, glucose and insulin level are high by the simulation result, which could be due to 
insulin resistance. It is thus estimated HGP delay may be longer than 22 min for Type 2 
diabetics. Besides, with τ1 increasing, the lower limit of glucose decreases quickly, 
probably resulting in hypoglycemia. This is a potential danger for diabetics. 
 
 
Figure 3.11. Phase plane of glucose and insulin in the plasma (A), and plasma and ISF glucose 
level difference (B) when τ1 changes. Both glucose and insulin in plasma reach a steady state with 
τ1 ≤12 min. 
 
3.4.6 Insulin Secretion Delay τ2 
IS delay was reported to be in the range of 0-23.5 min [65]. An initial range of 0-20 
min of τ2 was assumed for the simulation. 
When τ2 increases, the ranges of glucose and insulin widen significantly. A critical 
value for τ2 to sustain the oscillations is found to be about 4 min (Figure 3.12.A). For IS 
delay shorter than 4 min, the oscillations are damped quickly. For τ2 within 4-12 min, 
glucose concentration is changing within the optimal range. With τ2 increases from 12 
min, glucose and insulin level are higher than normal, which may be caused by insulin 
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resistance. Therefore, the IS delay is estimated to be longer than 12 min for Type 2 
diabetics. The possibility of occurrences of hyperglycemia at the peak is high with τ2 
longer than 12 min. 
 
 
Figure 3.12. Phase plane of glucose and insulin in the plasma (A), and plasma and ISF glucose 
level difference (B) when τ2 changes. 
 
3.4.7 Combined Effect of the Two Delays 
Based on the results in section 3.4.5 and section 3.4.6, the sums of τ1 and τ2 are 
equal to approximately 24 min. In subsequent simulation to investigate the influence of 
the two delays on the system, the sum of the delays is kept constant.  
A critical value for the sum of the two delays is found to be about 24.6 min. When 
the sum of the two delays is greater than the threshold, the ultradian oscillation can be 
sustained. The critical sum of the two delays is quite close to the single delay within the 
range of 0-23.5 min suggested by [65]. Due to compartment split in our work, the time 
delay of glucose transporting and utilization always exists, which was included into IS 
delay in [15]. A critical value for HGP delay to stimulate oscillation was reported at 
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0.109223 [63]. In our simulation, due to the compartment split of insulin subsystem, 
when HGP delay is equal to 0, the oscillation is sustained (Figure 3.13.A). 
When HGP delay increases from 0 to 24.6 min, glucose and insulin concentrations 
in two compartments change stably within the normal ranges, and glucose concentration 
difference between two glucose compartments is always within the optimal range (Figure 
3.13.B). This indicates a good degree of stability of inter-regulation of glucose-insulin 
system.  
The simulation result implies that the glucose-insulin regulatory system may reach 
the optimal situation with the constant sum of the two delays. A possible physiological 
explanation may lie on the negative feedback of human body. For normal subject, when 
one of the two delays becomes longer, in order to bring the body system back to stability 
quickly, the other delay may be accordingly decreased. For the diabetics, regardless of 
Type 1 or Type 2, the ability of adjusting one or both delays may be impaired, and 
therefore hypoglycemia or hyperglycemia may be induced.  
 
 
Figure 3.13. Phase plane of glucose and insulin in the plasma (A), and plasma and ISF glucose 




3.4.8 Glucose Infusion Rate Gin 
Ultradian oscillations of glucose and insulin are assumed to be caused by the 
instability of glucose-insulin regulatory system. Different glucose infusion rate is 
suggested to affect the critical delay time of stimulating ultradian oscillation. Glucose and 
insulin level are higher caused by higher glucose infusion rate (GIR). Ultradian 
oscillation was revealed by experiments during 3 meals daily, oral glucose intake, 
continuous enteral nutrition and constant glucose infusion (refer to Figure 1 in [44]).  In 
this section, effect of varied glucose infusion rate on the oscillatory behavior of glucose-
insulin system is investigated.  
With GIR changing from 0 to 250 mg/min, glucose and insulin concentration in 
both compartments increase with growing GIR. Varying GIR has significant effect on the 
amplitudes of glucose and insulin concentration. Oscillations of glucose and insulin 
sustain for moderate GIR; and ultradian oscillation of glucose-insulin system damps 
under small and large GIR, which agrees with the result in [16]. A range of 60-190 
mg/min for GIR is observed to sustain the oscillation (Figure 3.14.A). Oscillation damps 
out and the dynamic system goes for a steady-state for the infusion rate out of the range. 
An upper limit of GIR but without lower limit to stimulate the ultradian oscillations was 
reported in [15], which may be not reasonable in the sense of physiology. When glucose 
rise caused by low glucose intake is relatively small, glucose concentration would be 
reduced to normal level by insulin quickly, and regulation time is too short to induce 
oscillations of glucose and insulin.  
When GIR is kept between 60-115 mg/min, plasma glucose level can be within the 
optimal range 90-120 mg/dL (Figure 3.14.B). The difference of glucose concentration in 
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the two compartments changes from 18% to 25% with growing GIR, and it increases with 
climbing plasma glucose level in each cycle (Figure 3.14.C).  
 
 
Figure 3.14. Phase plane of glucose and insulin in the plasma (A), range of plasma glucose and 
insulin (B), and plasma and ISF glucose level difference (C) when GIR changes.  
 
3.4.9 Discussion 
In existing studies on oscillatory behavior, the interaction between plasma glucose 
and ISF glucose was often ignored. The glucose measured by implantable glucose sensor 
in artificial pancreas is usually the ISF glucose concentration. It is necessary to study the 
dynamic relationship between plasma glucose and ISF glucose before an insulin therapy 
can be applied. The aim of this chapter is to investigate the oscillatory behavior of the 




Under constant glucose infusion rate, the values of the seven parameters are varied in our 
simulation study. The simulation results agrees with existing studies [15, 16, 44], and 
physiological effect relevant with the parameters is discussed. 
When one of the six parameters: the four m parameters and the two delays varies, 
plasma and ISF glucose changes in the same direction with variable concentration 
difference. For insulin, when insulin transfer rate m1, m2 or ISF insulin clearance rate m4 
changes, insulin in the two compartments changes in the opposite direction and in the 
same direction when one of the other parameters is altered. This implies that m1, m2 and 
m4 may have more significant effect on insulin distribution between the two 
compartments. 
 When each parameter is within the range sustaining the ultradian oscillations, ISF 
glucose concentration is 14% -28% lower than that in plasma compartment. Glucose level 
difference between plasma and ISF always changes, and is different for rising and falling 
side. For the parameters changing in the optimal range, the level difference curves 
changes clockwise, which indicates the plasma glucose changes faster than ISF glucose in 
the rising side.  This agrees with the report from [13] that the change of ISF was less than 
that in plasma when glucose was increasing and was greater when glucose was 
decreasing. There are some situations where the glucose level difference changes in a 
different way. When m4 is equal to 0.2 (Figure 3.8.B), with the closed curve changed 
anticlockwise, glucose level difference during falling was larger than that during rising. 
This may be due to the greater IDGU in subcutaneous tissues that could lower ISF 
glucose quickly.  
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Three lags have often been investigated in existing studies: lag between plasma and 
ISF glucose, lag between plasma glucose and plasma insulin, and lag between plasma and 
ISF insulin. The simulation results are shown in Figure 3.15 and Figure 3.16. 
 
                     
Figure 3.15. The effect of m1, m2, m3, and m4 on the change of lag and oscillation period. The 
oscillation period was divided by 10 in Figure 4.15 and Figure 4.16. In Figure 3.15 and Figure 3. 
16, the definitions for the four lines in each panel are as following: green dash lines with star 
marker: lag of ISF glucose behind plasma glucose; blue solid lines: oscillation period; black dot 
lines with diamond marker: lag of ISF insulin behind plasma insulin; and red dash-dot lines with 













From the simulation, ISF glucose often lags behind plasma glucose for about 3-6 
min (green dash lines with star marker in Figure 3.15 and Figure 3.16). It approaches the 
physiological lag of 5 min suggested by [13]. However, ISF glucose begins to lead 
plasma glucose with increasing insulin transfer rate from plasma to ISF m1, ISF insulin 
clearance rate m4 and HGP delay τ1. Larger m1 and m4 can increase insulin transfer to ISF 
and glucose utilization respectively; and longer HGP delay would decrease the glucose 
production rate into plasma compartment. Thus ISF glucose begins to lead plasma 
glucose. It was also suggested that increased glucose clearance from ISF would decrease 
the lag [82]. 
55 
 
In plasma compartment, glucose is observed to lead insulin to peak and fall for 
about 10-20 min (red dash-dot lines with circle marker in Figure 3.15 and Figure 3.16). 
This is significantly affected by plasma insulin degradation rate m3 and IS delay τ2. The 
lag becomes shorter when m3 increases or τ2 decreases. The reason might be that larger 
insulin degradation in plasma and shorter IS delay would stimulate or accelerate insulin 
secretion, and hence the lag is reduced. 
Plasma insulin always leads ISF insulin for 10-15 min with significant change by 
altering ISF insulin clearance rate m4 (black dot lines with diamond marker in Figure 3.15 
and Figure 3.16). When m4 increases, the lag decreases quickly. A possible explanation is 
that increased larger ISF insulin clearance rate would accelerate insulin distribution.  
Lo nger HGP d elay τ1 or IS delay τ2 would increase the oscillation period of the 
dynamic system and result in higher glucose concentration (blue lines in Figure 3.15 and 
Figure 3.16). Glucose fluctuation becomes more significant when one of the two delays 
increases. Large fluctuation of glucose should be avoided in glucose regulation. The two-
delay bifurcation was also discussed in some studies [63, 64]. Keeping the sum of the two 
delays constant is considered in our simulation. Figure 3.13.A shows that as long as the 
sum threshold is greater than 24.6 min, the ultradian oscillation can be sustained with 
plasma glucose level always changing in the optimal range even if HGP delay τ1 or IS 
delay τ2 is equal to 0. The glucose-insulin system seems to have reached the optimal 
situation. Apart from the lag between plasma glucose and plasma insulin (red dash-dot 
lines with circle marker in Figure 3.16.C), the other two lags and oscillation period do not 
have significant change.  
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Although different GIR has significant influence on the amplitudes of insulin and 
glucose, it hardly affects the oscillation time and lag effect among the four state variables 
(Figure 3.16.D). The oscillation period of the regulatory system is almost constant at 
about 120 min, plasma insulin lags behind plasma glucose for 12-15 min, ISF insulin lags 
plasma glucose for about 27 min, and a lag of about 3 min exists between plasma glucose 
and ISF glucose. Investigation on varying GIR reveals that the effect of constant GIR on 
oscillatory behavior of the oscillatory glucose-insulin system is not important, which 
agrees with the result reported in [16]. 
In this chapter, the four m parameters of insulin dynamics, the two delays and GIR 
are analyzed for their influence on the glucose-insulin regulatory system, their ranges are 
estimated for sustaining the oscillation of glucose-insulin system, and ranges for different 
subjects are discussed. The estimated parameter range for different subjects is shown in 
Table 3.7. The seven parameters are related with the disease relevant to irregular blood 
glucose level. The resultant effect of these parameters on the lag between glucose and 
insulin in the two compartments provide an insight on the distribution and metabolism of 
glucose and insulin in quick- and slow-equilibrating organs and tissues. 
 
Table 3.7. Ranges of model parameters for different subjects. 
 1m  2m  3m  4m  1τ  2τ  GIR 
Sustain oscillation 0.02-0.08 0.01-0.04 0.1-0.6 0-1 14≥  4≥  60-190 
Optimal/Normal 0.03-0.06 0.02-0.04 0.2-0.3 0.02-0.05 14-22 4-12 60-115 
Sub-healthy 0.06-0.08 0.01-0.02 0.1-0.2 0-0.02 / / / 
Type 2 diabetics 0.02-0.03 / 0.3-0.6 >0.05 >22 >12 / 






Glucose level measurement and insulin infusion are often implemented in the 
subcutaneous tissues in artificial pancreas. Understanding the dynamics of glucose and 
insulin in the subcutaneous tissues is important in the regulation of blood glucose level.  
We proposed a new two-compartmental model of glucose-insulin interaction with two 
explicit delays that can study the interaction of glucose in different organs and the 
oscillatory behavior of the glucose-insulin system.  
In this chapter, glucose and insulin space are split into plasma compartment and ISF 
compartment respectively. The four m parameters of insulin dynamics, the two delays 
and GIR are analyzed for their influence on the glucose-insulin regulatory system. The 
ranges of the seven parameters are estimated for sustaining the oscillation of glucose and 
insulin, and ranges for different subjects are discussed based on simulation results. The 
effect of these parameters on the oscillatory system is related to diseases and irregular 
blood glucose level. The investigation of lag between glucose and insulin in the two 
compartments sheds light on the distribution and metabolism of glucose and insulin in 
quick- and slow-equilibrating organs and tissues. A model was studied in this chapter that 
can effectively deal with concentration of glucose and insulin in the ISF compartment. 
This is important for the research and development of a clinical viable artificial pancreas. 
The characteristics of the model agree with most of the dynamic properties 
proposed up to now, and support the hypothesis that the ultradian oscillation of glucose 
and insulin in human body may originate from the interaction and negative feedback 
between glucose and insulin. This is consistent with our result that ultradian oscillations 
can still sustain with constant sum of HGP and IS delay, which may be a reflection of the 
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negative feedback between glucose and insulin. By removing insulin secretion from the 
model to simulate the situation of Type 1 diabetes, ultradian oscillation does not occur 
under constant external glucose infusion. This may indicate that insulin secretion function 







4 Model of Glucose-Insulin System with 
Subcutaneously-Injected Insulin 
4.1 Introduction 
Reducing glucose fluctuation or duration of hyperglycemia and hypoglycemia can 
improve the morbidity of diabetics. Insulin delivery and glucose measurement via 
subcutaneous route has advantages over intravenous route: low incidence of infection, 
less pain and discomfort, and ease of administration. When insulin is administered 
intravenously, exogenous insulin enters vein directly. It is difficult to implement insulin 
delivery for ordinary people, and may cause infection due to improper operation. The 
development in subcutaneous administered insulin analogues makes the management of 
diabetes more effectively. The pharmacokinetic profile of the latest rapid and basal-acting 
analogues can mimic pancreatic insulin secretion better than previous insulin. When 
insulin is delivered subcutaneously, the delivery site is subcutaneous tissues. Insulin can 
be infused using an insulin pen or insulin pump by ordinary people. Subcutaneous 
delivery of insulin is safer and more convenient for daily use compared with intravenous 
delivery. Intravenous insulin delivery is sometimes applied in the intensive care unit so 
that it takes less time for insulin to take effect.  
The most common therapy for diabetic patients is multiple insulin injections 
subcutaneously based on three or four glucose level measurements daily. Besides, in 
closed-loop glucose control system (artificial pancreas), glucose measurement and insulin 
administration are often implemented in the subcutis. The dynamics of glucose and 
insulin in the subcutis is thus important to achieve tight glucose control. With good 
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knowledge of the physiology of blood glucose regulation, an accurate glucose-insulin 
interaction model and an efficient glucose control algorithm could be developed. 
The absorption of injected insulin is complex and can be affected by many factors 
(site and depth of injection, temperature [83], exercise [84], concentration and volume of 
injected insulin [85], species [86], etc.). The mechanism of how insulin absorption 
kinetics influenced by insulin dose size, concentration, insulin crystals etc. was explained 
in a recent study by quantitative description [87]. Poor absorption of insulin is apparent 
for patients with severely impaired endogenous IS. The mean absorption levels for 
different insulin were estimated in [88].  
Published insulin absorption data was analyzed by non-compartmental analysis and 
pharmacokinetic methods. By this method, Friedberg et al. suggested the mean 
absorption level for different insulin (70% - 80% for regular and lispro, 30% or less for 
NPH, and 30% - 40% for lente insulin) [88]. Insulin remains in the subcutaneous fat layer 
for some time after the rapid injection. Possible reasons of delayed absorption at large 
injection volumes are: self-depression, saturable diffusion through the capillary 
membrane, and that the injected solution may create a separate space in subcutis, thus 
reducing contact with capillary system [89]. 
Polymerization and /or degradation may happen and result in decreased amount of 
insulin and slow rate of insulin diffusion from the injection site. The reduction of insulin 
amount due to polymerization and local degradation was represented by an effectiveness 
factor in [90]. Insulin degradation is relevant to insulin action, and is as important as that 
of insulin secretion.  
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The degradation of subcutaneously injected insulin has been found to occur in rat 
[91-93], pig [94] and human [93, 95, 96]. A considerable amount of insulin was degraded 
at the injection site in some studies [94]. About 40% of the injected insulin was reported 
to be degraded at the injection site of diabetic rats [93]. Local degradation of 
subcutaneously injected insulin was considered to be insignificant or relatively small [89]. 
In Type 1 diabetic patient, the SC degradation of infused insulin was reported to be 
insignificant and negligible [96]. In [97], total degradation of subcutaneous delivered 
insulin was reported to be less than 20% over 4 hours period based on the best-fitting 
parameters. Contrary to the view, a considerable amount of insulin was degraded at the 
injection site in some studies [94, 98, 99]. By studying both control subjects and in 
subjects who may have large SC degradation of insulin, a degradation rate of about 2% 
per milligram per minute was estimated in [100].  
Due to the varying pharmacokinetics of injected insulin, glycemic control by 
insulin injection or continuous insulin infusion in the subcutis is challenging and meets 
significant practical difficulties to become a stable and consistent therapy. Qualitative and 
quantitative estimation of insulin kinetics after SC injection is useful for efficient dosing 
as well as reducing the fluctuation of glucose level. 
Subcutaneous tissue is becoming the main measurement site of glucose sensor and 
administration sit of exogenous insulin in the future artificial pancreas. It is important to 
understand the kinetics interactions of glucose and insulin between plasma and 
subcutaneous tissues. Glucose dynamics was modeled using a one-compartment system 
in some models [15, 44], ignoring the dynamics of glucose in subcutis. Varying 
degradation and absorption of endogenous insulin for different diabetic patient changes 
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the effective dosage of insulin for glucose regulation. Hyperglycemia or hypoglycemia 
may be caused by insufficient or overdose of insulin subcutaneously-injected. The 
ignorance of the physiological changes (e.g., defective absorption or accelerated 
degradation of insulin [101, 102]) on the subcutaneously-injected insulin causes loose 
control of glucose concentration for diabetic patients. 
In Chapter 3, a two-compartment model describing  the oscillatory behavior of 
glucose – insulin system was proposed to investigate the influence of model parameters 
on the system and interactions between quick- and slow-equilibrating tissues and organs 
[103].  There was no exogenous insulin in this model. In this chapter, with exogenous 
insulin delivered subcutaneously, dynamics of both glucose in subcutis and 
subcutaneously-injected insulin [104] are considered for Type 1 and Type 2 diabetic 
patients. A submodel mimicking the kinetics of injected insulin in the subcutis is 
included.  Two compartments expressing the plasma and subcutaneous tissues are used to 
express glucose subsystem, and insulin degradation in the subcutaneous tissues, two 
absorption channels for insulin are considered for the subcutaneously-administered 
insulin. The model of glucose – insulin system with insulin subcutaneously injected is 
evaluated using the clinical data of diabetic inpatients. This model considering the 
dynamics of subcutaneously-injected insulin simulates the situation of diabetic patient 
receiving subcutaneous insulin delivery, and helps derive control algorithms for treatment 
of diabetic patients. 
 
4.2  Models of Subcutaneous Insulin 
The kinetics of insulin injected subcutaneously has been investigated widely. Many 
models mimicking insulin kinetics differ essentially in the subcutaneous insulin 
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absorption, Plasma insulin, in most case, is modeled using a single compartment, except 
that by Hovorka et al. [105].  
 
4.2.1 Compartmental Models 
Kobayashi et al. used a one-compartment model with a delay to model the 
absorption of short-acting insulin injected or infused subcutaneously [106]. It was 
proposed that insulin absorption kinetics for the two modes: continuous infusion and 
bolus injection subcutaneously, did not have significant difference; and the insulin was 
degraded to the same extent using the two administration modes. The model diagram and 
equations were given by Figure 4.1 and Eq. (4.1), respectively. 
                                
                   Figure 4.1. Diagram of SC insulin model proposed by Kobayashi et al.. 
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where x1 is the amount of insulin in the subcutaneous depot (μU), i is plasma insulin 
(μU/mL), ka and ke (min-1) are the rate constants for absorption and elimination 
respectively, Vd (L/kg) is the distribution volume, τ (min) is the time lag and u(t) (U/min) 
the rate of insulin administration. 
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Kraegen and Chisholm suggested a two-compartment model of subcutaneous 
insulin distribution: SC volume and plasma insulin volume [97]. Subcutaneous volume 
consisted of two connected pools. Insulin was modeled to move from a first to a second 
pool in the SC volume before delivered to the plasma volume. Insulin degradation was 
assumed from the two pools in the SC volume respectively, linear with the insulin 
amounts in the two pools (Figure 4.2). The model equations were given by Eq. (4.2).The 
insulin absorption delay was suggested to be important for clinical implications therein.  
                                 
Figure 4.2. SC insulin model proposed by Kraegen and Chisholm. 
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where x1 and x2 are the insulin masses in the subcutaneous compartments, u(t) is the 
subcutaneous infusion rate, kd is the rate constant of insulin degradation in subcutis, and 
k21 and ka are the rate constants describing insulin transport within the subcutaneous 
space and from the subcutaneous depot to plasma, respectively; i is plasma insulin 
concentration, and ke the elimination rate constant. 
In [97], total degradation of SC delivered insulin was reported to be less than 20% 
over 4 hours period based on the best-fit parameters. In their later work [96], in Type 1 












insignificant and negligible, and local accumulation in SC space was considerable. The 
insulin absorption delay was suggested to be important for clinical implications. 
A simple linear model was developed and identified using data of diabetic patients 
by Puckett and Lightfoot to predict plasma insulin and provide some insights on clinical 
issues (i.e., interpatient and intrapatient variation and insulin overlapping) [90]. The 
model structure was similar to that in [97]. The model was composed of three 
compartments: pocket insulin (formed by injected insulin solution), interstitium insulin 
and blood insulin (Figure 4.3). The model was described in Eq. (4.3).  
                             
Figure 4.3. SC insulin model proposed by Puckett and Lightfoot. 
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where x1 is the subcutaneous insulin mass per unit plasma distribution volume, x2 is the 
interstitial fluid insulin mass per unit plasma distribution volume and i is plasma insulin 
concentration. D is the injected dose, a is the effectiveness factor accounting for insulin 
degradation at the injection site and Vd is the insulin distribution volume. ka is the rate 
constant from subcutaneous depot to interstitial fluids and from interstitial fluids to blood, 
ke is the rate constant of plasma insulin elimination. ib is the constant plasma term 
describing the effect of ultralente insulin and h(t)=1 for 0<t<24 h. 
x2 







The pure time delay in [106] was replaced using the interstitium compartment. A 
component for long-acting ultralente insulin and representation of cumulative effect of 
multiple injections were considered.  
A three-compartment linear model was proposed by Shimoda et al.  to develop an 
insulin infusion algorithm used on a wearable artificial pancreas [107]. The SC insulin 
was modeled using two compartments: insulin at the injection site and insulin proximal to 
plasma, with exogenous insulin injected into the compartment representing injection site. 
The model was expressed using three differential equations (Eq. (4.4)). The insulin 
degradation in the SC tissues was more significant than that in [97].  
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where x1 is the sc insulin mass where the injection takes place, x2 is sc insulin mass 
proximal to plasma and i is plasma insulin concentration. The rates constants kd and ke are 
the degradation constants in the sc tissue and plasma respectively, Vd is plasma 
distribution volume. 
A five-compartment model to describe the dynamics of insulin was presented by 
Hovorka et al. [105]. The model explored the insulin distribution in systemic plasma, 
hepatic plasma, interstitial fluid, and insulin bound to the liver and peripheral receptors. 
The receptor-mediated and non-receptor-mediated insulin degradation were taken into 
account in the model. Another linear absorption model of subcutaneously administered 
insulin Lispro was proposed and included into a glucoregulatory model to develop a 
model predictive controller in Type 1 diabetic subjects by Hovorka et al. [45]. The 
subcutaneous insulin absorption model was represented by a two-compartment chain, and 
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the plasma insulin was modeled using a single compartment (Figure 4.4). A long delay of 
over 90 min was observed between insulin SC delivery and its peak action. The delay 
may be relevant to the insulin absorption delay in SC depot and the insulin action 
duration. 
                             
Figure 4.4. SC insulin model proposed by Hovorka et al.. 
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where S1 and S2 are a two-compartment chain representing absorption of subcutaneously 
administered short-acting (e.g. Lispro) insulin, u(t) represents administration (bolus and 
infusion) of insulin, and tmax,I is the time-to-maximum insulin absorption. The insulin 
absorption rate (appearance of insulin in plasma) is obtained as UI = S2(t)/t max,I.  
The plasma insulin concentration I(t) is described as 
                                               ( ) ( ) / ( ).I I eI t U t V k I t= −  (4.6) 
ke is the fractional elimination rate and VI is the distribution volume. The model 
represents three actions of insulin on glucose kinetics: 
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X1, X2 and X3 represent the (remote) effects of insulin on glucose distribution, glucose 
disposal and HGP; ka1, ka2 and ka3 represent deactivation rate constants, and kb1, kb2 and 
kb3 represent activation rate constants. 
Wilinska et al. proposed eleven alternative models of insulin Lispro kinetics under 
bolus and continuous delivery subcutaneously of Type 1 diabetes [104]. Insulin delivery 
mode, two channels of insulin absorption, effect of insulin dose on its clearance and 
absorption, insulin degradation at the injection site and insulin association state were 
assessed in the models. The models were validated using data from seven Type 1 diabetic 
patients based on the principle of parisimony and physiological plausibility. Two 
absorption channels and local insulin degradation of insulin were indicated in the four-
compartment model (Figure 4.5) best representing the experimental data. Different with 
most insulin absorption models with linear insulin degradation, Michaelis – Menten 
dynamics was used to model the local insulin degradation. The insulin subsystem with 
injected insulin was described using four differential equations in Eq. (4.8). 
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   (4.8) 
where Q1a, Q1b and Q2 are insulin masses in the channels, Q3 is insulin mass in plasma 
compartment, k is the proportion of u, the insulin input, that passes through the slower 
channel, ka1 and ka2 are the transport rates between compartments, ke is insulin clearance 
rate of from plasma by the liver and kidneys, and LDa and LDb are the Michaelis-Menten 
degradation in two channels, respectively.  
 
4.2.2 Non-Compartmental Models 
A pharmacokinetic model simulating the kinetics of subcutaneously-injected insulin, 
empirically derived from previous studies and included in the glucose – insulin model, 
was used to estimate the time course of plasma insulin for different combinations of 
preparations (regular, NPH, lente, and ultralente) [108]. The effect of changing insulin 
regimen, dose, or meals timing was investigated in the glucose control program to 
demonstrate the performance of glucose control in Type 1 diabetic patients. In this model, 
the percent of insulin amount absorbed from the subcutaneous space is given by: 
 % 50( ) 100 ( ) 100 100 / ( ),s s sA t A t t T t= = − +  (4.9) 
where s describes absorption rate of the various insulin preparations and T50 is the time 
interval to reach a 50% absorption of the injected insulin. T50 was described as: 
 50 ,T aD b= +  (4.10) 
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where D is insulin dose, and a and b express different values for different insulin 
preparation. Insulin absorption velocity, the time derivative of A(t) multiplied by the 
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where ke is the rate constant for insulin degradation and Vd is the plasma insulin 
distribution volume. 
Mosekilde et al. presented a model utilizing the chemical relationship between 
insulin oligomers to describe the absorption process of subcutaneously injected soluble 
insulin [89]. In this model, insulin was presumed to be present in three forms: a low 
molecular weight form (dimeric insulin), a high molecular weight form (hexameric 
insulin) and an immobile form where molecules were bound to the tissue (bound insulin). 
Three compartments were used to express the insulin present in three forms: hexameric 
insulin, dimeric insulin and bound insulin in the subcutaneous depot. By presuming that 
mainly dimeric insulin penetrated the capillary wall, the dimeric insulin compartment was 
connected with plasma insulin, and controlled the absorption rate. Effective diffusion 
constant for insulin in subcutis, absorption rate of dimeric insulin, equilibrium constant 
between hexameric and dimeric insulin, binding capacity for insulin in the tissues, and 
the average life time for insulin in its bound state can be determined using this model. 
Only the dimeric state can be absorbed into plasma. Solving the non-linear coupled 
differential equations is computationally burdensome when dose, volume and 
concentration are considered. Due to the number of parameters, model parameters are a 
priori identified from literature. The model is theoretically unidentifiable and 
computationally burdensome to implement. 
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The model by Mosekilda et al. [89] was simplified by Trajanoski et al. for ease of 
parameter estimation [109]. The insulin binding in the subcutaneous space was assumed 
to be negligible at therapeutic concentrations. The model was further extended to describe 
the absorption of both soluble insulin and monomeric insulin analogues. The influence on 
the absorption of various injection volumes, concentration, and injection depth was 
investigated for soluble and monomeric insulin. The mechanism of how insulin 
absorption kinetics influenced by insulin dose size, concentration, insulin crystals etc. 
was explained in a recent study by quantitative description [87]. The model of Trajanoski 
et al. was further extended to include the long-acting basal insulin Glargine [110].  
The non-compartmental models capture published insulin absorption kinetics well 
and are more accurate physiologically than the compartmental models. However, 
computational cost is prohibitive compared to compartmental models, especially if it is 
used for a real-time diabetes decision system or an in silico simulation tool. These six 
model [90, 97, 106-109] were reviewed critically and discussed by Nucci and Cobelli 
[111]. Other reviews were also available to present insulin absorption kinetics in subcutis 
[62, 112]. 
Subcutaneous tissue is to become the main measurement site of glucose sensor and 
administration sit of exogenous insulin in the future artificial pancreas. It is important to 
understand the kinetics interactions of glucose and insulin between plasma and 
subcutaneous tissues. Glucose dynamics was modeled using a one-compartment system 
in some models [15, 44], ignoring the dynamics of glucose in subcutis. Different 
degradation and absorption of endogenous insulin for different people changes the actual 
dosage of insulin effecting on glucose regulation. Hyperglycemia or hypoglycemia may 
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be thus caused by insufficient or overdose of insulin subcutaneously-injected. For 
diabetic patients, loose control of glucose concentration may arise from the ignorance of 
the physiological changes on the subcutaneously-administered insulin.  
In this chapter, the dynamics of both glucose in subcutis and subcutaneously-
injected insulin [104] are considered. A variant of the glucose-insulin model in [103] with 
meals and insulin subcutaneously-administered is proposed for diabetic patient. Two 
compartments expressing the plasma and subcutaneous tissues are used to express 
glucose subsystem, and insulin degradation in the subcutaneous tissues, two absorption 
channels for insulin are considered for the subcutaneously-administered insulin. This 
model considering the dynamics of subcutaneously-injected insulin simulates the 
situation of diabetic patient receiving subcutaneous insulin delivery, and helps derive 
control algorithms for treatment of diabetic patients. 
 
4.3  Modeling Glucose-Insulin System with Subcutaneously-Injected Insulin 
Oscillatory behavior of glucose-insulin system in human body has been observed 
during in vivo and in vitro experiments [51-54, 57]. In the recent models studying the 
ultradian oscillations of glucose and insulin, glucose is often modeled as a one-
compartment system [15, 18, 44, 60], which ignores the dynamics of glucose in subcutis. 
In this model, dynamics of both glucose in subcutis and subcutaneously injected insulin 
[104] are considered. Following the model proposed previously in [103], a model for 
diabetic patient with meal inputs and insulin injection was proposed.  
 
4.3.1 Model of Glucose and Insulin Subsystems 
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The organs with large blood flow relative to their interstitial volume may have a 
rapid rate of equilibrium (e.g., liver, heart, kidney, etc.), while other poorly perfused 
tissues have a slow equilibrating rate (e.g., muscle and adipose tissues). The first 
compartment, plasma and rapidly-equilibrating organs, is named plasma for short; and the 
slowly-equilibrating tissues is expressed as subcutaneous tissues compartment (SC 
compartment for short). The model structure was shown in Figure 4.6, and the complete 
model was described in Eq. (4.12) and (4.13). 
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In the insulin subsystem, the state variables in the insulin subsystem are plasma 
insulin Ip (mU), Q1a, Q1b and Q2 (mU) in the SC compartment. SC insulin Ii (mU) is 
assumed to be the sum of the three states in the SC compartment. After exogenous insulin 
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(u: mU/min) is administered subcutaneously, local insulin degradation (LDa, LDb: 
mU/min) occurs at the injection site in the two pathways of insulin absorption. Injected 
insulin moves from a first (Q1a: mU) to a second (Q2: mU) pool in the slow channel 
before reaching plasma. Vmax_LD (mU/min) is the saturation rate for continuous infusion 
and bolus; and Km_LD (mU) is the insulin mass at which insulin degradation is equal to its 
half maximal value. p (unitless) is the proportion of insulin flux passing the slow channel. 
ka1 and ka2 are transfer rates (min-1) in the two channels accordingly. Insulin clearance in 
plasma compartment is represented by the rate parameter ke (min -1). 
 
Figure 4.6. Model of glucose-insulin system with subcutaneously-injected insulin. 
 
 
For the glucose subsystem, two state variables were considered: plasma glucose Gp 
(mg) and SC glucose Gi (mg). The concentration of SC glucose was measurable during 
experiments. The state variables in the insulin subsystem were plasma insulin Ip (mU), 
Q1a, Q1b and Q2 (mU) in the SC compartment. Vgp, Vgi, Vip, and Vii were the distribution 
volumes of plasma glucose, SC glucose, plasma insulin and SC insulin accordingly, 
which was estimated respectively as 12%, 10%, 4.5% and 10% of body weight [14, 31, 
45, 81]. τ1 and τ2 are HGP and IS, respectively. BW is the bodyweight of the subject. 
75 
 
In the insulin subsystem, after exogenous insulin (u: mU/min) is administered 
subcutaneously, local insulin degradation (LDa, LDb:mU/min) occurs at the injection site 
in the two pathways of insulin absorption. Injected insulin moves from a first (Q1a: mU) 
to a second (Q2: mU) pool in the slow channel before reaching plasma. Vmax_LD (mU/min) 
is the saturation rate for continuous infusion and bolus; and Km_LD (mU) is the insulin 
mass at which insulin degradation is equal to its half maximal value. p (unitless) is the 
proportion of insulin flux passing the slow and fast channel. ka1 and ka2 are transfer rates 
(min-1) in the two channels accordingly. Insulin clearance in plasma compartment is 
represented by the rate parameter ke (min-1).  
IDGU in this model was different with that in [103]. The process of IDGU was 
presented as a function of the sum of insulin mass in the SC compartment. The value of 
insulin exchange rate between SC and plasma compartment e followed that in [44]. The 
effect of diabetes on insulin secretion and IDGU in diabetic patients was estimated by α 
and β [18]. Smaller α and β implies less insulin secretion from pancreas and increasing 
insulin resistance in the diabetic patients, respectively. For the definitions of other 
parameters, refer to previous chapter. 
 
4.3.2  Models of Meal 
When a healthy patient eats a meal, the carbohydrates are broken down into glucose, 
galactose and fructose, with galactose and fructose transformed quickly into glucose. Fats 
are converted to phospholipids, triglycerides, and cholesterol; and proteins are converted 




Insulin increase results in increased glucose uptake by liver and peripheral tissues, 
keeping plasma glucose level within normal range. Glucose level of a healthy patient 
rarely goes over 140 mg/dL, even during a meal. 
For a diabetic patient, insulin effect on glucose regulation strongly depends on the 
quality of insulin therapy, depending on the insulin amount administered and the time of 
administration. If insulin level is very low, insulin is not enough for glucose uptake by 
liver and peripheral cells; and low insulin level results in relatively high glucagon level, 
which actually causes higher glucose level in the blood. The time of insulin 
administration plays a major role in maintaining normoglycemic conditions. Early 
administration would cause hypoglycemia before the meal is absorbed and 
hyperglycemia at the end of meal, because insulin is not sufficient for glucose utilization 
from the end of the meals. Late insulin administration would result in hyperglycemia at 
the beginning of the meal and hypoglycemia at the end of the meal or shortly after. 
Glucose from gut absorption is assumed to enter plasma directly into the accessible 
compartment with clearance by first pass splanchnic degradation. Glucose appearance 
rate in plasma was described with a mono-compartment model by Fisher [113], as given 
in Eq.( 4.14). b represents the absorption rate of the meal, A is meal size and tmeal 
represents the beginning time of meal digestion. 
 ( ) exp( ( )).mealD t A b t t= − −  (4.14) 
Plasma described by two compartments, an accessible and non-accessible 
compartment, was suggested by Hovorka et al. [45]. A two-compartment chain with 
identical transfer rates was used to describe digestion, gastric emptying, and the gut 
absorption rate directly into plasma, as shown in Eq. (4.15). Ameal represents the percent 
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availability of the meal consumed, Mmeal is the size of meals, and tmax represents the time 




exp( / )( ) .meal mealM A t t tD t
t
−
=  (4.15) 
In the study by Dalla Man et al. [114], model was evaluated against a linear and 
non-linear three-compartment model. This model in Eq. (4.16) consists of dual stomach 
compartments with a non-linear gastric emptying rate. Gastric emptying kempt is a 
constant in the linear model; and in the non-linear model gastric emptying is described by 
a hyperbolic tangent function, as shown in Eq. (4.17).  
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qsto1(t)  Amount of glucose in the stomach (solid phase), 
qsto2(t)  Amount of glucose in the stomach (liquid phase), 
δ(t)   Impulse function, 
D Amount of ingested glucose, 
qgut(t)   Glucose mass in the intestine, 
k21         Rate of grinding, 
kempt   Rate of gastric emptying, 
kabs  Rate of intestinal absorption, 
f Fraction of intestinal absorption appearing in plasma, 
kmin      Minimum gastric emptying rate, 
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kmax    Maximum gastric emptying rate. 
The glucose absorption model, relevant to the size of carbohydrate (CHO) in the 
meal, followed that in [18, 115] with k and b as listed in Table 4.1. The value of k for 15 
g and 7.5 g carbohydrate (CHO) was estimated by fitting the curve of k and meal size 
(Figure 4.7). For each meal began at time tm, the glucose intake rate Gm(t) was shown in 
Eq. (4.18). u(t-tm) was the unit step function with unity value only when t ≥ tm. Gin(t) was 
calculated by integrating each meal intake Gm. This model of meal absorption was used in 
the following simulation for its simplicity.
 
                         
                            2 2 2( , , ) exp( ( ) / 2 ) / ( ).m m m mG t k b kt t t b b u t t= − − × −  (4.18) 
 
Table 4.1. Parameters value for the glucose absorption model. 
 7.5 g CHO 10 g CHO 15 g CHO 30 g CHO 60 g CHO 75 g CHO 
b 80 








4.4 Clinical Evaluation of Model with Subcutaneously-Injected Insulin 
4.4.1 Material 
Model cannot give meaningful prediction unless its parameters are accurately 
determined. Average parameter values in literature are often used for modeling, such as 
the organ volumes and blood flow rates of dogs in [116] or humans was used by Sorensen 
[20]. Patient parameters is identified by fitting the model to patient data and selecting 
reasonable parameter values which give the closest fit to the data. 
Twenty five cases (three Type 1 and twenty-two Type 2) with subcutaneously-
injected insulin were studied. Information of gender, age, bodyweight, glucose 
concentration, insulin injections and meals were recorded for each subject. The glucose 
was measured regularly by finger prick before meals. Three meals (60 g, 30 g or 15 g 
CHO contained) and snacks (15 g or 10 g CHO contained) were offered for the subjects. 
Mixtard 30 or short-acting insulin of individually dosage was injected 3-15 min before 
meals. Each insulin injection lasted for about 1 minute.  
In this model, rate parameters in insulin subsystem (ka1, ka2), two delays (τ1 and τ2), 
and two parameters (α and β) expressing the dysfunction of the diabetic patients are 
adjustable. Model constants of the model are listed in Table 4.2. Since blood glucose 
level was measured by finger prick, modeled glucose level in SC compartment was used 
to match that of the clinical glucose data. The first glucose data in each case was set as 
the initial glucose concentration. The initial values of the model parameters were 
determined by adjusting the simulated glucose level with the measured glucose level 
manually and then refining the parameters with successive iterations.  
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Table 4. 2. Model constants of our model. 
Parameter Value Unit 
k1 0.032 min-1 
k2 0.02 min-1 
ke 0.37 min-1 
p 0.55 unitless 
Vmax_LD 235 mU/min 
Km_LD 65 mU 




Model-based and sliding scale protocols have been clinically tested for glucose 
regulation. Model-based methods can be accurate, but require identifying patient specific 
parameters and capturing all of the observed dynamics. Currently, most common 
parameter identification methods are non-linear, and sometimes computationally intense 
for real-time use. An accurate identification method is important for refining and testing a 
model. For non-linear methods, fitting or prediction error can be caused by the dynamics 
not captured or not finding the global minima. Using different starting points may find a 
better optimal solution, with increased computational time.  
The most commonly used method for fitting parameters in compartment models is 
non-linear recursive least squares (NRLS) [19, 117, 118]. This method requires a range of 
initial values to produce optimal result. NRLS is computationally intensive as well [19], 
particularly with longer periods of data. Iterative, Bayesian and gradient descent based 
methods have been used in many different forms [39, 119, 120]. These methods are 
computationally intensive and not necessarily robust to noise in the data, and are not 
necessarily generalizable to broader situations. Overall, traditional methods, such as 
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NRLS, generate results with some potential limitations which is dependent on the specific 
problems. These methods require repeated simulations resulting in significantly added 
computation. 
The integral method integrates the differential equations of the model and converts 
the problem to match areas under curves [121]. Using numerical integration and 
measured data, the problem can be converted into a least squares problem. The numerical 
integration can further filter the data and make it robust to noise. Finally, significant 
computation effort can be saved because it does not require gradients or re-simulation of 
the model. The integral method has been used in may glycemic control studies [121-123] 
and in other biomedical models [124]. 
In this section, the model parameters are estimated using least square method which 
fits a set of observations with the proposed model by estimating the values of a subset of 
the unknown parameters. Our objective is to adjust the parameters to best fit the clinical 
data comprising glucose level, insulin injection dosage and meals of anonymous diabetes 
inpatients. Each data set consists of N data pairs (tj, Gj). The least squares method finds 








=∑  (4.19) 
is minimum where the residuals (errors) rj are given by 
 ( , ),Mj j jr G G t θ= −  (4.20) 
where θ=[ ka1, ka2, τ1, τ2, α, β] is a parameter vector to be estimated. Gj and GM(tj, θ) are 
the measured glucose level and modeled glucose level at time tj, respectively. The 
minimum value of S occurs when the gradient for each parameter  
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is zero. 
In nonlinear system the derivatives of S do not have closed solution. With initial 
value of the parameters given, the parameters can be estimated by iterative approximation: 
 1 .k ki i i iθ θ θ θ+≈ = + ∆  (4.22) 
k is the iteration number and Δθ is the shift vector. At each iteration, the model can 
be linearized by approximation using Taylor series expansion at θk: 
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Substituting into the gradient equation, we obtain 
 
1 1
2 ( ) 0.
N m
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j s
J y J θ
= =
− ∆ − ∆ =∑ ∑  (4.25) 
The nonlinear problem of matching the clinical data with the proposed model is 
approximated as a linear least square problem which can be solved using Gauss-Newton 
algorithm. 
To the best of our knowledge, there has not been any glucose-insulin model 
including the sub-model of subcutaneously-injected insulin for Type 2 diabetic patients. 
Type 2 diabetes is more prevalent than Type 1 diabetes, and the metabolism of glucose-
insulin system and automatic glucose control is more complex for Type 2 diabetes. 
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Developing a model to simulate the metabolism of glucose-insulin system including 
subcutaneously-delivered insulin for Type 2 diabetes is especially important for the 
derivation of control algorithm of closed-loop insulin delivery system.  
Most of them modeled external insulin to be infused directly into the plasma 
compartment such as the Minimal model [36]. This is not applicable for closed-loop 
glucose regulation system applying subcutaneous glucose monitoring and subcutaneous 
insulin delivery. In order to evaluate the performance of modeling the dynamics of 
glucose and insulin, our model was compared with Hovorka model [45]. Since the 
Hovorka model was proposed only for Type 1 diabetic patient, clinical data of the three 
Type 1 cases were fitted using Hovorka model for comparison. 
In Hovorka model, glucose subsystem was represented by two compartments: 
glucose in accessible and non-accessible compartments.  Six differential equations were 
used to describe insulin absorption and action system. Six parameters in the model 
(glucose transfer rate k12, insulin elimination in plasma compartment ke, endogenous 
glucose production EGP extrapolated to zero insulin level EGP0, insulin sensitivity of 
distribution, disposal and EGP: SIT, SID, SIE) were adjusted to fit the clinical data of three 
Type 1 subjects. With the values of other model parameters remained the same as that of 
[45], initial values of the six model parameters were determined by adjusting the 
simulated glucose level with the measured glucose level manually. 
 
4.4.3 Results and Discussion 
The accuracy is determined by normalizing the sum of the square error (SSE) with 
the number of glucose measurement of each case. Figure 4.8 shows the normalized SSE 
of the 25 cases using our model and SSE of the three Type 1 cases using Hovorka model. 
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With the initial values of glucose and insulin level determined explicitly, our model was 
compared with Hovorka model [45] using clinical data of three Type 1 cases (Case 1, 11, 
and 17), as shown in Figure 4.9; and Case 20 and Case 3 of Type 2 patients with 
respectively smallest and largest normalized SSE values are presented in Figure 4.10 to 
illustrate the curve fitting results of Type 2 cases. The information of the five diabetic 
subjects is shown in Table 4.3; and the size and time of glucose intake and insulin 
injection are shown in Table 4.4.  
 
 




Table 4.3. Information of the five diabetic subjects. 
 Case 1 Case 3 Case 11 Case 17 Case 20 
Diabetes Type Type 1 Type 2 Type 1 Type 1 Type 2 
Age 22 46 32 39 70 
BW (KG) 58 40.9 82 66.6 52.7 
Gender Male Male Male Male Male 
HbA1c / 16.8% 10.9% / 12.2% 




Table 4.4. Time and size of meal intake and insulin injections of the five subjects. 
Case Glucose Insulin 
Case 
1 
Time (min) Size (g) Time (min) Dose (U) 
540,  660, 750, 900, 
1020, 1320 
60, 15, 60, 15, 
60, 15 
600, 660, 720, 785,840, 
930, 1660, 1730, 1767, 
1830, 1895, 900, 1050, 
1115, 1180, 1240, 1300, 
1360, 1420, 1480, 1540, 
1660 
5, 2.5,1, 1, 1, 1, 
1, 1, 1, 1, 1, 1.5, 
1.5, 1.5, 1.5, 1.5, 




0, 1440, 1980, 2880, 
3120, 4320, 240, 540, 
1680, 3420, 420, 840, 
1860, 3300 
60, 60, 60, 60, 
60, 60, 30, 30, 
30, 30, 15, 15, 
15, 15 
0, 540, 1980, 3420, 1440, 
2880, 4320 




0, 2645, 720, 2195, 
2715, 3645 
45, 45, 15, 15, 
15, 15 
0, 240, 1215, 1455, 1695, 
1935, 2715, 3435, 480, 720, 
960, 2485, 2955, 3195 
4, 4, 4, 4, 4, 4, 4, 
4, 2, 2, 2, 2, 2, 2 
Case 
17 
10, 370, 1450, 1810, 
180, 1620 








10, 1090, 2530, 850, 
2290, 3730, 4030, 
1450, 2890, 4330, 
960, 1260, 2700, 
3070, 4140, 4510 
30, 30, 30, 60, 
60, 60, 60, 60, 
60, 60, 15, 15, 
15, 15, 15, 15 
5, 845, 1085, 4025, 3725, 
2525, 2285, 3255, 4325 
6, 8, 8, 8, 28, 12, 




The proposed model can mimic the change patterns of the observed glucose level, 
and demonstrate ultradian oscillations in Figure 4.9 and Figure 4.10. Although the same 
model structure for short and intermediate acting insulin was applied, our model was 
demonstrated to be adequate for simulating human glucose – insulin system. The value of 
parameters of our model and Hovorka model of the Type 1 cases is listed in Table 4.5. 





Table 4.5. Parameters value of our model and Hovorka model of three Type 1 cases. 
 Our model Hovorka model 
Case 1 ka1=0.34, ka2=0.19, τ1=38, β=0.95 
EGP0=0.016, ke=0.238, k12=0.116, 
SIT =0.00392, SID=0.00062, SIE=0.029 
Case 11 ka1=0.24, ka2=0.13, τ1=31, β =0.88 
EGP0=0.0145, ke=0.14, k12=0.095, 
SIT =0.0031, SID=0.00034, SIE=0.033 
Case 17 ka1=0.13, ka2=0.16,  τ1=29, β =0.61 
EGP0=0.017, ke=0.21, k12=0.105, 
SIT =0.0019, SID=0.00021, SIE=0.013 
 
 
Table 4.6. Parameters range of our model for the twenty-two Type 2 subjects. 
Parameter Range Parameter Range 
ka1 0.095—0.29 τ1 30—49 
ka2 0.085—0.22 τ2 31—51 
α 0.21—0.97 β 0.23—0.75 
 
 
In Figure 4.9, simulated glucose concentration of our model agreed well with that 
of the clinical data. Insulin dosage injected is much less than that of Type 2 cases in 
Figure 4.10 although there is no insulin secreted by the pancreas. It agrees with the large 
β in Table 4.5, implying lower insulin resistance in Type 1 subjects. The sharp change of 
glucose concentration in Type 1 cases, which is significantly different from the disrupted 
oscillations of other Type 2 cases, indicates that the insulin secretion plays an important 
role of stimulating the ultradian oscillations of glucose and insulin. The Hovorka model is 
demonstrated to be able to agree with the clinical data of the three Type 1 cases. Glucose 
level changed more gradually compared with that of our model in Figure 4.9 (A) with 
multiple small-dosage insulin injections. With the reduced sampling of glucose 
measurement in Figure 4.9(B) and (C), simulation results of Hovorka model have higher 
glucose peak levels than ours, which should be avoided for diabetic subjects. There are 
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less sharp changes in the estimated glucose levels with our model under sparse glucose 
measurement in the three Type 1 cases. With more frequent glucose sampling, our model 
could better simulate glucose change, and explain the interactions between glucose and 
insulin in the terms of physiology and pathology of diabetes. 
 
 
Figure 4.9. The comparison result of our model with Hovorka model (Case 1: A, Case 11: B, 
Case 17: C). Modeled glucose level and clinical data were shown in the top panel. In the bottom 
panel the blue solid and black dash curves represented glucose intake rate using our model and 
Hovorka model, respectively (mmol/min); and the green solid line represented insulin injection 





Figure 4.10. The fitting result of measured glucose with estimated glucose level using our model 
for the Type 2 cases with the smallest (A: Case 20) and highest (B: Case 3) normalized SSE. In 
the bottom panel, the red dash curve and the blue lines represented glucose intake rate (mmol/min) 
and insulin injection dosage (mU), respectively. In the left figure, the parameters were estimated: 
ka1=0.14, ka2=0.13, τ1=37, τ2=45, α=0.42, β=0.52. In the right figure, the parameters were 




In Figure 4.10 (A), most data points can be simulated using our model. Measured 
glucose level is significantly decreased after insulin injections, agreeing well with the 
simulated glucose change pattern using our model. Subcutaneous glucose level oscillates 
mostly between 10-14 mmol/L. However, glucose level decreases sharply immediately 
after insulin injection which is due to the fact that subcutaneous tissue is one of the main 
glucose utilization locations. Glucose oscillations between two successive insulin 
injections are mostly stimulated by endogenous insulin secretion. The subject in Case 20 
is a 70 years old male Type 2 patient with weight 52.7 kg. HbA1c (Glycated hemoglobin) 
measured before 4-day glucose monitoring in hospital was 12.2%. Although this subject 
is older than the one in Case 3 (Figure 4.10 B), average glucose level is much lower than 
Case 3. The situation of this subject is better than Case 3 with lower HbA1c. Larger α and 
β than Case 3 demonstrates more insulin secretion and less insulin resistance of this 
subject. The insulin transport rates and the two delays are all in the reasonable ranges.   
In Figure 4.10 (B), although the sparse glucose measurement resulted in missing 
information of glucose change, our model has been demonstrated to be robust in 
modeling the change in glucose level. This Type 2 case has the largest normalized SSE, 
and the subject is a 46 years old male patient with weight 40.9 kg. HbA1c measured 
before 3-day glucose monitoring was 16.8%. HbA1c for normal is often below 6%, 
which implies that glucose control for this subject is not good in the past several months. 
High glucose level of this Type 2 subject may be caused by severely impaired function of 
pancreas and increased insulin resistance. This agrees with the small values of α and β 
estimated using the clinical data of this subject. High insulin transport rate between the 
SC and plasma compartment from two absorption channels ka1 and ka2 in Figure 4.10 (B) 
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implies quick transfer of insulin, which was reasonable for a thin male. Delay of insulin 
secretion τ2 was quite long, slowing secretion of endogenous insulin; and small α and β 
demonstrated weak ability of insulin secretion and high insulin resistance in the insulin 
sensitive tissues. The above factors may explain the extremely high HbA1c. Extended 
period of high glucose level would result in malfunction of many organs and further 
aggravate the symptoms of diabetes. There is a significant mismatch of modeled glucose 
level with the measured glucose at 2040 min. It is much higher than the glucose levels 
measured at the same time on the previous day (600 min) and the following day (3480 
min) with similar size of insulin dosage in each day. The considerable differences 
between the theoretical estimation and measurement might be caused by other 
disturbances or large change of the subject’s condition. Glucose-insulin system may be 
disrupted by severe diabetes, which changes the parameter values and makes the 
estimation of glucose level using mathematical models more complicated. Frequent 
change of model parameters is surmised to be affected by the severity of diabetes, which 
may cause proposed glucose-insulin unable to predict glucose level for severe diabetic 
patients. This may explain the simulation result in Figure 4.10 that fitting with clinical 
data in Case 20 is better than that of Case 3. 
The large interpatient variation on the model parameters indicates the necessity of 
identifying individual parameters. Regular recalibration is therefore necessary for patients 
using commercial continuous glucose monitoring system (CGMS) with automatic insulin 
delivery. The curve fitting between model simulation and clinical data is limited by low 
sampling frequency, measurement noise, and lack of measurement of pertinent variables 
in the clinical data. These factors introduce a considerable uncertainty on the exact 
90 
 
parameter value. When the model was used to predict glucose change, this can be 
improved by glucose controller calculating optimal dosage of injected insulin under more 
frequent glucose sampling. Glucose level could be regulated back to normal range and 
reduced the fast change of glucose level. 
The rate parameter in the SC insulin compartment ka1 and ka2 is relevant to the 
diffusion of injected insulin from SC to plasma through slow and fast channels, 
respectively. More insulin can be delivered to the plasma with larger value of rate 
parameters. In the peripheral tissue where insulin is administered, insulin resistance is 
significantly high which slows down insulin transport via capillary wall [125]. Smaller 
value of ka1 and ka2 implies high insulin resistance in the subcutis. The diffusion and 
action of insulin could also be protracted by thick adipocytes in the subcutis [69].  
HGP delay is relevant to the plasma insulin’s effect on glucose production by liver; 
and IS delay is dependent on the action time of insulin secretion stimulated by the plasma 
glucose. The estimated range of τ1 in this work approximates the value of 25-50 min 
reported in [44]. Insulin secretion delay τ2 was proposed in the range of 0-23.5 min [65]; 
however the experimental results on normal subject is probably different from that of 
diabetic patients. A value of 50 min of τ2 was used in numerical simulation [61], which 
was within the our proposed range. HGP and IS delay are related to the action of glucose 
production by liver and insulin secretion by pancreas, which is significantly affected by 
the situation of the subjects. For younger and healthier subjects, liver and pancreas takes 
faster action to the change of insulin and glucose level, respectively. Long HGP delay 
would probably induce hypoglycemia when external glucose input is not given in time, 
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and hyperglycemia is possible to be caused by long IS delay, especially after meals intake 
which makes glucose level increase fast.  
The parameters α and β indicated the ability of insulin secretion and glucose 
utilization in diabetic patient respectively. α was set to be 0 for Type 1 cases. This was 
different from the situation in [18] that Type 1 subjects had endogenous insulin secretion. 
Decrease in insulin secretion was reported in the elder patients [126], which agrees with 
our result that smaller value of α often occurred in the older subjects. The values of β for 
Type 2 cases are smaller than Type 1 cases. The impairment of IDGU is more significant 
in Type 2 diabetic patient due to insulin resistance in the subcutis. Moderate-to-severe 
muscle insulin resistance may happen in lean Type 2 subjects, while there is no further 
defect in insulin action in obese Type 2 subjects [127].  
Possible mechanisms contributing to insulin resistance included variable capillary 
density [128], large local degradation of insulin [95], and alternations of the receptor-
mediated transendothelial insulin transport [125]. These factors may affect transport of 
glucose and insulin between blood and subcutis and subsequent glucose utilization by 
insulin-sensitive cells, and play an important role of diffusing insulin from injection site 
to other parts of the body and altering of postprandial glucose metabolism.  
     Obesity and aging may deteriorate the situation of diabetic patients. In an obese 
subject, thick fat layer delays the diffusion of injected insulin followed by larger local 
degradation of insulin; reduced number and impaired function of glucose transporter 
slows glucose transport from plasma to insulin-sensitive cells; and impaired IS and 
sensitivity would reduce glucose uptake in the periphery and cause hyperglycemia. Obese 
rat hearts was reported to have decreased total glucose transporter number [129]. Insulin 
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resistance is a common for obese individuals, where the pancreatic β-cell is less sensitive 
to increment of plasma glucose level is compared with subjects with normal insulin 
sensitivity.  
Changes in anthropometric characteristics with increasing age (e.g., increase of fat 
mass and visceral fat) may cause insulin resistance in humans [130]. The decline in 
insulin action has been demonstrated to be relevant to the increasing age under 
euglycemic-hyperinsulinemic clamp conditions [131]. Glucose stimulated insulin 
secretion was reported to be functionally impaired in aging rats [126]. It is obvious that 
functions of body organs (e.g., pancreas, liver, kidney, blood vessels, etc.) are retrograded 
due to aging. The metabolism of glucose and insulin is disrupted and diabetes would be 
further aggravated.  
 
4.5 Summary 
Subcutaneous tissue is to become the main measurement site of glucose sensor and 
administration sit of exogenous insulin in the future artificial pancreas, in any case, it is 
important to understand the kinetics interactions of glucose and insulin between plasma 
and subcutaneous tissues. Subcutaneous tissues cause significant degradation for injected 
insulin, and absorption of endogenous insulin is different for different people, which 
changes the actual dose of insulin taking effect on glucose regulation. Hyperglycemia or 
hypoglycemia is to be caused by insufficient or overdose of insulin subcutaneously-
injected. A model including the dynamics of glucose in the subcutaneous tissues and the 
dynamics of subcutaneously-administered insulin is thus proposed. 
93 
 
The number of patients with Type 2 diabetes is more than that of Type 1 diabetes, 
and the metabolism of glucose and insulin, and glucose regulation is more complex for 
Type 2 diabetes. There has not been a glucose-insulin model including the dynamics of 
subcutaneously-injected insulin for Type 2 diabetic patients up to now. therefore, 
developing a model to simulate the metabolism of glucose-insulin system including 
subcutaneously-delivered insulin for Type 2 diabetes is especially important for the 
derivation of control algorithm of closed-loop insulin delivery system. Our study could be 
a possible solution for glucose control of Type 2 diabetes. 
In this chapter, a model of glucose – insulin system was developed to simulate the 
dynamics of glucose and insulin in diabetic patients receiving insulin injection. 
Quantitative estimation of insulin absorption and transport is useful for efficient dosing as 
well as reducing the fluctuations of glucose level. The slowly-equilibrating compartment 
(SC compartment) of insulin was divided into three compartments to simulate the local 
degradation and different absorption rate of subcutaneously-injected insulin. The effect of 
concentration, volume, etc. of injected insulin was not considered in our proposed model.  
The glucose-insulin model including subcutaneous insulin was fit to clinical data of 
diabetic patients. The simulated glucose level agrees well with the measured glucose 
level. The fitting result using our model was compared with that of existing model using 
Type 1 cases, and our model obtains smaller SSE, especially when the glucose 
measurements are sparse. Six model parameters were estimated and analyzed 
physiologically and pathologically. 
Irregular oscillation of glucose level and influence of meals and insulin injections 
are observed in Type 2 cases. The glucose – insulin model is able to mimic the dynamics 
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of glucose and insulin based on long term clinical monitoring of the diabetic subjects. 
The estimated kinetic parameters are physiologically meaningful, and could be related to 
the subject’s dysfunction due to diabetes and the pathology of diabetes.  
     Obesity and aging have significant effect on the situation of diabetic patients. In 
an obese diabetic subject, thick fat layer delays the diffusion of injected insulin followed 
by larger local degradation of insulin, related to the model parameters ka1 and ka2. 
Impaired IS and insulin sensitivity would reduce glucose uptake in the periphery and 
cause hyperglycemia. This agrees with smaller α and smaller β for obese subjects 
implying less insulin secretion and less glucose utilization due to high insulin resistance. 
Insulin resistance is a common for obese individuals, where the pancreatic β-cell is less 
sensitive to increment of plasma glucose level compared with subjects with normal 
insulin sensitivity. In addition, reduced number and impaired function of glucose 
transporter for obese subjects slows glucose transport from plasma to insulin-sensitive 
cells.  
The decline in insulin action and glucose stimulated IS has been demonstrated to be 
relevant to the increasing age. Changes of anthropometric characteristics with increasing 
age (e.g., increase of fat mass and visceral fat) may cause insulin resistance in humans. 
Liver and pancreas takes faster action for younger and healthier subjects. For diabetic 
patient, long HGP delay τ1 would probably induce hypoglycemia when external glucose 
input is not given in time. Hyperglycemia is possible to be caused by long IS delay τ2, 
especially after meals intake which makes glucose level increase fast. 
Severe diabetes disrupts functions of some organs, which changes model 
parameters values from time to time, and complicates the modeling glucose-insulin 
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dynamic system. Glucose measurement and insulin delivery in subcutaneous tissues are 
important in the development of artificial pancreas. The proposed model incorporating 
subcutaneous glucose and subcutaneously-injected insulin, and its validation with patient 




5 Glucose Control Using Model Predictive Controller  
5.1 Model Predictive Control 
The most common therapy for diabetic patient is multiple insulin injections 
subcutaneously based on three or four glucose level measurements daily. It is the so-
called ‘open-loop control’. This method is not only painful and inconvenient, but may 
result in hyperglycemia and hypoglycemia. Keeping glucose within the narrow 
normoglycemia range 70-120 mg/dl or 4-7 mmol/L (different ranges were reported: 70-
120 mg/dl [132, 133], 80-110 mg/dl [134, 135] or 70-110 mg/dl [136, 137]) is difficult 
for a diabetic patient using the ‘open-loop control’. Closed-loop glucose control methods 
have been studied to replace the existing therapies due to its convenience and safety [134, 
138-140]. 
The study of human physiology and pharmacokinetics makes MPC suitable for 
glucose control. MPC has some advantages over conventional control methods such as 
PID control to regulate blood glucose level. The anticipatory ability of MPC can reduce 
the fluctuations of blood glucose by controlling insulin delivery carefully, compensate for 
dead time existing in glucose-insulin system [141], and handle the constraints problem 
and patient variability considering hardware specifications of insulin pump [142]. Due to 
its robustness and stability, MPC has been applied widely in the development of artificial 
pancreas [45, 143-145]. 
In MPC, future system output is predicted based on a model simulating the dynamic 
system subject to the change of system disturbance. Future control action to the system is 
calculated using control history and current system measurements by optimizing an 
objective function and considering the tracking error and constraints of system.  
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The MPC control strategy uses current measured output and past input to predict 
the future input within the control horizon and future output trajectory within the 
prediction horizon (Figure 5.1) by solving a finite horizon optimal control problem. The 
cost function (Eq. 5.1) is minimized with respect to the inputs under the system model’s 
state dynamics and constraints of states and inputs. After we obtain the solution of the 
FHOCP, a feedback control law can be obtained by applying the first part of the solution 
to the system, as shown by the diagram of overall control process in Figure 5.2. 
          
Figure 5.1. MPC strategy (Adapted from the Model Predictive Control Toolbox of Matlab). 
 
As shown in Figure 5.1, the future outputs for the prediction horizon P are 
predicted at each instant k using the process model. The predicted output depends on the 




The future control signals u are calculated by optimizing a determined criterion to keep 
the process close to the determined reference trajectory r. The criterion is often a 
quadratic function of the errors between predicted output and the determined reference 
trajectory.  
Applying MPC in blood glucose control, the predicted glucose level is calculated P 
sample times into future. The aim is to minimize the square of the difference between the 
predicted glucose level and the desired setpoint trajectory by adjusting M future insulin 
infusion rates. In each step, only the first in the M future insulin infusion rate is 
implemented. At the next sampling instant, the procedure would be repeated with a new 
control move. Control moves are included in the objective function: 
                                2 2 1
1 1
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= − + ∆ ≥∑ ∑                                       (5.1) 
where λ is the weighting on manipulated input increment Δu, r is the desired glucose 
level setpoint, yˆ  is the predicted glucose level, and k is the sample time index. MPC can 
enforce the system constraints explicitly. This is important for a glucose control system 
with physiological constraints. 
 
 
Figure 5.2. Diagram of overall control process (Adapted from the Model Predictive Control 




The objective of designing a controller based on MPC is to mimic a healthy 
pancreas to regulate the glucose concentration for the diabetic patients. The controller 
should be able to keep glucose level within the normal range under different situations 
such as after meal intake, during fasting condition and during exercise as well. Therefore, 
as shown in Figure 5.2, measured disturbance v and unmeasured disturbance d are sent to 
the system together with the control input u; and the measured output including predicted 
output by the model and noise signal z is sent to the model predictive controller. 
 
5.2 Glucose Control using Two-compartment Model and Minimal Model 
To study the effectiveness of using MPC to regulate glucose level, the two-
compartment model in Chapter 3 is used to design a model predictive controller. The 
result of glucose regulation using our model is compared with that of Bergman’s minimal 
model with the same glucose disturbance. The ability of the two controllers to regulate 
glucose level in response to meal disturbance and unnoticed disturbance in plasma 
glucose compartment is investigated by analyzing the glucose response and the insulin 
infusion profile. The minimal model and two-compartment model are shown in Figure 
5.3 and Figure 5.4, respectively. There is no external insulin input in the two-
compartment model in Chapter 3. In agreement with minimal model that external insulin 
is input into plasma compartment, external insulin is added to the plasma insulin 
compartment in the two-compartment model. The nominal value of the two-compartment 
model parameters is adapted from Table 3.5; and the parameter value of minimal model 





Table 5.1. Parameter value of minimal model. 










The imposed constraints for insulin infusion rate and plasma glucose level of the 
two models in simulation are as follows [147]: 
                                 
0 80 / min,
16.7 / min   ,
4 / 7 / ,
u mU
u mU per sample time




                                 (5.2) 
where u is external insulin input, Δu is the change rate of u and y is measured plasma 
glucose level. The constraint on u maintain insulin level below 80 mU/L. Hard constraint 
on Δu ensure that insulin infusion rate change is within the capability of the pump, and 
gentle glucose reduction is more beneficial and safe for the patient. Constraint on y 
ensures glucose level is within the safe range by avoiding hypoglycemia. The 





Figure 5.3. Diagram of the Bergman minimal model in Simulink. 
 
 
Figure 5.4. Diagram of the two-compartment model in Simulink. 
 
In order to compare the performance of the two models in controlling glucose level, 
four different forms of meal intake were used: constant glucose infusion for 10 minutes 
for 3 times, constant glucose infusion, impulse glucose injection and exponentially 
decreasing glucose infusion. In the simulations in this chapter, it was assumed the models 
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can match the virtual glucose-insulin system in the human. The unnoticed glucose 
disturbance was set to happen randomly with positive or negative value in plasma glucose 
compartment to simulate unnoticed meal intake or unexpected exercise. This disturbance 
was set to take place less than 15 times during the simulation and last for 5 minutes each 
time, and the value of this disturbance was taken to be within -500 ~ 500 mg/min.  
Three times of constant glucose infusion for ten minutes is added to the plasma 
compartment. 10 g glucose was infused within ten minutes for the first and third time and 
20 g glucose for the second time. The simulation results are shown in Figure 5.5 and 
Figure 5.6.  
 
 
Figure 5.5. Simulation result using minimal model with three constant glucose infusions. From 
Figure 5.5 to Figure 5.12, A: Plasma glucose concentration (blue), upper and lower limit of 
normoglycemia range (red), and desired glucose level (green). In the simulations of this chapter, 
the prediction horizon and control horizon is set to be 10 and 5, respectively. The sampling time 





Figure 5.6. Simulation result using two-compartment model with three constant glucose infusions. 
 
In Figure 5.5.A, glucose level changes within the normoglycemic range most of the 
time. Slight hyperglycemia and serious hypoglycemia happen for several times for 
minimal model. The time of hypo- and hyperglycemia agrees with that of unnoticed 
glucose disturbance. The hyperglycemia and hypoglycemia is caused by large unnoticed 
disturbance in plasma glucose compartment. Noticed meal intakes and small unexpected 
glucose disturbances do not cause large change of glucose level under the regulation of 
MPC controller. In Figure 5.6.A, slight hyperglycemia happens with each meal intake. 
Glucose oscillates slowly with the meal intake and external insulin infusions as well. 
Unnoticed glucose disturbances do not cause any hyperglycemia or hypoglycemia. The 
effect of unnoticed disturbance is negligible for the two-compartment model, which is 
better than the minimal model. During the period without glucose input, external insulin 
input for minimal model is more than that of the two-compartment model. Less insulin is 
needed for the two-compartment model during the whole simulation. It is harmful for 
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patients with plasma glucose level lower than 60 mg/dL (3.3 mmol/L), and avoiding 
hypoglycemia is more important than avoiding hyperglycemia. The two-compartment 
model performs better than minimal model under this situation. 
 




Figure 5.8. Simulation result using two-compartment model with constant glucose infusion. 
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In Figure 5.7.A, when glucose is infused constantly, glucose level oscillates around 
the desired glucose level except when unnoticed glucose disturbances happen, and insulin 
infusion rate keeps increasing with the time. When large unnoticed glucose disturbance 
increases glucose input, hyperglycemia occurs for minimal model. The increase of 
glucose level caused by small glucose disturbance can be regulated by the MPC 
controller. When negative glucose disturbance occurs at around 100 min, there is a sharp 
increase of insulin infusion (Figure 5.7.B), and slight hypoglycemia occurs. The 
unreasonable result happens as well to the four times of positive glucose disturbances 
which cause fast decrease of insulin infusion. Insulin infusion rate should increases when 
more glucose enters plasma compartment due to unnoticed glucose disturbance. The 
unreasonable simulation result caused by the glucose disturbance may be the inability of 
minimal model to regulate glucose level caused by unnoticed disturbances, which may be 
improved by parameter tuning. 
Glucose level is regulated within normoglycemia for the two-compartment model 
except the single instance of slight hypoglycemia caused by the unnoticed decrease 
glucose level, as shown in Figure 5.8.A. Glucose oscillates within 4~6 mmol/L around 
the desired glucose level with a oscillation period 90~100 min. The oscillation period 
agrees with the simulation result in Chapter 3 for the two-compartment model with the 
same glucose infusion rate of 108 mg/dL. According to the time of insulin infusion and 
unnoticed disturbance, it is estimated that insulin infusion with amplitude larger than 40 
mU/min is caused by the large unnoticed disturbance. Insulin infusions with smaller 
amplitude regulate glucose level  within the normal range under constant glucose intake. 
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With the constant glucose intake and same unnoticed glucose disturbance, the two-
compartment model is better for glucose control compared with minimal model. 
 
 
Figure 5.9. Simulation result using minimal model with impulse glucose injection. 
 
 




After 25 g glucose is infused quickly, glucose level increases slightly under the 
effect of increasing infused insulin for minimal model in Figure 5.9. After the insulin 
infusion rate increases to its maximal value, it decreases slowly. Some small change of 
insulin infusion rate occurs on the time of unnoticed glucose disturbance. Hyperglycemia 
and hypoglycemia happen around the time of large glucose disturbance, the reason of 
which is similar to that of Figure 5.7. Glucose level of the two-compartment model 
increases sharply and slight hyperglycemia occurs after fast glucose intake in Figure 
5.10.A. Under the combined effect of increased insulin infusion and unexpected negative 
glucose disturbance with large amplitude, slight hypoglycemia occurs as well. The 
simulation result is similar to that of some diabetic patients that hyperglycemia occurs 
first after meal intake when the action time of insulin injected before the meal is too long; 
and hypoglycemia follows hyperglycemia after injected insulin takes effect to regulate 
glucose and overdose insulin is injected. As shown in Figure 5.10.A, glucose level keeps 
within the normal glucose range except some obvious change of glucose level caused by 
unnoticed glucose disturbance. Glucose level reaches the steady state quickly after the 
glucose disturbances, and insulin amount infused for the two-compartment model is 









Figure 5.12. Simulation result using two-compartment model with glucose infusion decreasing 
exponentially. 
 
When glucose intake rate is set to be decreased exponentially from 50 mmol/L from 
60 min to 180 min and unnoticed glucose disturbances are included in the minimal model, 
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glucose level can be kept in the desired range most of the time (Figure 5.11.A). However, 
slight hyperglycemia and severe hypoglycemia take place around the time of some large 
glucose disturbances. During the period without disturbance, glucose level is close to the 
desired glucose level. With the effect of disturbance on insulin infusion ignored, insulin 
infusion rate increases to the maximal value and decreases slowly with the decreased 
glucose intake rate. The decrease rate is much slower than that of the two-compartment 
model in Figure 5.12.B. For the two-compartment model, insulin infusion caused by the 
exponentially decreased glucose intake stops before 100 min (Figure 5.12.B), and glucose 
level reaches the lower limit of normoglycemia at around 100 min (Figure 5.12.A), which 
avoids hypoglycemia in time and shows the good performance of MPC controller. 
Glucose level almost changes within the normoglycemia with some negligible glucose 
levels out of this range.  
For the four forms of glucose infusion rate, the MPC controller using the two-
compartment model shows some advantages over that of using minimal model: it causes 
less hypoglycemia and hyperglycemia, less insulin is used and glucose change caused by 
unnoticed glucose disturbance is better controlled. The two-compartment model proposed 
in the thesis is possible to be applied in the future closed-loop insulin delivery system. 
 
5.3 Glucose Control with Injected Insulin 
The glucose-insulin model with subcutaneously-injected insulin in Chapter 4 and 
the Hovorka model [45] were used to design a model predictive controller. With the same 
glucose disturbance, the results of glucose regulation using the two models are compared 
to study the effectiveness of using the two MPC controllers to regulate glucose level. The 








Figure 5.14. Diagram of the Hovorka model for Type 1 diabetic patients in Simulink. 
 
 
The model parameters of the three Type 1 cases were estimated in Chapter 4 using 
our model and Hovorka model. In this section, the model parameters estimated, the same 
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initial values of the model states and meal intakes of the two models are used in the MPC 
controllers; and glucose level using the two MPC controllers is to be compared with that 
controlled by manually insulin injections. For the five diabetic subjects, two situations for 
the two MPC controllers were proposed: noticed meal intake is the only glucose input, 
and besides noticed meal intake, unnoticed glucose disturbances in the plasma 
compartment occur at random time. 
In the five diabetic cases, case 1, case 11 and case 17 are Type 1 cases; and case 20 
and case 3 are Type 2 cases with the best and worst fitting result in Chapter 4. The 
simulation results of the Type 1 cases under the two situations are shown from Figure 




Figure 5.15. Simulation result of MPC controller using Hovorka model (left) and our model (right) 
to regulate glucose level of Type 1 diabetic patient (case 1). From Figure 5.15 to Figure 5.20, 
Figure 5.22 and Figure 5.23, black stars represent the measured glucose level, red lines represent 





When there is no glucose disturbance in the system (Figure 5.15), glucose level 
controlled by Hovorka model controller reduces fast from initial hyperglycemia and reach 
normal glucose level around 200 min, which is faster than that of using our model (450 
min). However, severe hypoglycemia happens from 600 min using Hovorka model 
controller while glucose level controller using our model reaches the ideal level after 600 
min. Glucose level regulated by the controller using our model is higher than measured 
glucose level before 400 min, which is caused by the limited insulin infusion rate of 
insulin pump. Hovorka controller fails to control glucose level for case 1, while the 
controller using our model is able to regulate glucose level well.  
 
 
Figure 5.16. Simulation result of MPC controller using Hovorka model (left) and our model (right) 
to regulate glucose level of Type 1 diabetic patient (case 1) with unnoticed plasma glucose 
disturbance. 
 
When unnoticed glucose disturbances are added to the system (Figure 5.16), 
compared with simulation results in Figure 5.15, glucose level changes significantly 
using Hovorka model, however glucose level controlled by our controller almost remains 
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unchanged with some negligible changes. Severe hypoglycemia and hyperglycemia 
happen as well to the system using Hovorka model. Hyperglycemia after 200 min is 
stimulated by glucose disturbance and hypoglycemia is improved by glucose input from 
glucose disturbances.  
 
 
Figure 5.17. Simulation result of MPC controller using Hovorka model (left) and our model (right) 




Figure 5.18. Simulation result of MPC controller using Hovorka model (left) and our model (right) 





For glucose regulation of case 11, hypoglycemia often happens using Hovorka 
controller when there is no glucose disturbance (Left subplot of Figure 5.17). Glucose 
level oscillates around normoglycemia range stimulated by oscillating insulin infusion 
with period about 250 minutes. When glucose disturbance is included, due to glucose 
disturbance, the oscillation of glucose level is disrupted, severe hyperglycemia occurs 
several times, and hypoglycemia is improved in the length of time for Hovorka model 
(Left subplot of Figure 5.18). Hovorka model controller cannot eliminate the effect of 
unnoticed disturbance on glucose level. Glucose level regulated by our controller is much 
lower that measured glucose level, and our controller is shown to be able to regulate 
glucose level well under these two situations. Glucose reaches normal level fast and 
remains around the ideal glucose using our controller. Glucose disturbances result in 
negligible change to glucose level under the regulation of our controller. The MPC 




Figure 5.19. Simulation result of MPC controller using Hovorka model (left) and our model (right) 




When there is no glucose disturbance for case 17 (Figure 5.19), glucose level 
controlled by Hovorka model decreases slowly, reaches normal glucose range at 500 min, 
and hypoglycemia takes place from 2000 min. Insulin keeps infusing after glucose lower 
than 4 mmol/L, which is unreasonable and may be explained by the inability of Hovorka 
model controller to regulate glucose level for case 17. However, glucose level is well 
regulated by our controller. Glucose level decreases to normal level at around 100 min, 
and it remains close to the ideal level (Right subplot of Figure 5.19). Except the period 
0~100 min, insulin infusion dosage by our controller is small compared with that of 
Hovorka model controller.  
 
 
Figure 5.20. Simulation result of MPC controller using Hovorka model (left) and our model (right) 
to regulate glucose level of Type 1 diabetic patient (case 17) with unnoticed glucose disturbance. 
 
 
With glucose disturbance introduced into the system, the time of hypoglycemia 
increase for glucose level regulated by Hovorka model controller (Left subplot of Figure 
5.20). Hypoglycemia takes place when the meal intake is zero. Insulin keeps infusion 
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during the period of hypoglycemia, which is similar to the simulation result when there is 
no glucose disturbance. As shown in the right subplot of Figure 5.20, glucose level is 
well regulated within the normoglycemia range. Insulin infusion rate during the periods 
without meal intake is small to facilitate glucose utilization for the Type 1 diabetic 
subject. Under the effect of glucose disturbance and infused insulin, glucose always 
changes around the ideal level. The parameters’ value of Hovorka model was estimated 
using sparse glucose level measurements for case 17, which may cause the failure of 
glucose control using Hovorka model controller. Glucose is better regulated for case 17 
using our controller, which is able to avoid hyperglycemia and hypoglycemia, cost less 
insulin, and regulate glucose close to the ideal level. 
 
 
Figure 5.21. Insulin dosage used in the simulations of glucose control using Hovorka model (Blue 
squares and circles represent insulin cost without and with glucose disturbance, respectively), our 
model (Red squares and circles represent insulin cost without and with glucose disturbance, 
respectively.), and in clinical experiment for the three Type 1 cases (Green stars represent insulin 
dosage injected in the clinical experiment). The y axes is displayed in log form. 
 
Total insulin dosage infused by the two controllers for the three Type 1 cases under 
the two situations were calculated, as shown in Figure 5.21. Insulin cost using the two 
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controllers is less than that of manual insulin injections during clinical observation. 
Insulin infused by Hovorka model controller is more than that of using our model. Insulin 
used to control glucose by our controller is close regardless of the inclusion of glucose 
disturbance, while large difference of insulin dosage infused exists under the two 
situations using Hovorka model controller. Insulin used for case 1 in clinical observation 
was less than that in simulation. However, glucose level regulated by our controller is 
much lower than measured glucose level (Right subplot of Figure 5.15), and glucose 
remains close to the ideal level under the regulation effect of MPC controller. 
 
 
Figure 5.22. Simulation result of MPC controller using our model to regulate glucose level of 
Type 2 diabetic patient (case 20) without glucose disturbance (left) and with glucose disturbance 






Figure 5.23. Simulation result of MPC controller using our model to regulate glucose level of 
Type 2 diabetic patient (case 3) without glucose disturbance (left) and with glucose disturbance 
(right). The total insulin dosages for the two situations are 32.1 U (left) and 32.5 U (right), 
respectively.  
 
Glucose of the two Type 2 cases regulated by our controller decreases quickly to 
the ideal level with insulin infused in the maximal rate during this period (Figure 5.22 
and Figure 5.23). After glucose reaches the ideal level, glucose level remains almost 
unchanged with the stimulation effect of infused insulin on glucose utilization. Glucose 
level under the regulation of our controller is much lower than measured glucose level. 
Severe hyperglycemia often takes place using manual insulin injections, as shown by 
clinical data of glucose level in the figures. When glucose disturbance is included in the 
system, glucose has some small changes around the ideal level; and insulin infusion is 
significantly different from that of the situation when there is no glucose disturbance.  
When there is no glucose disturbance introduced into the system, insulin dosage 
infused by the controller for case 20 and case 3 was 57.6 U and 32.1 U. It is much lower 
than the insulin dosage used in clinical observation, which is 115 U and 76 U for case 20 
and case 3, respectively. Due to the combined effect of positive and negative glucose 
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disturbance, the total insulin cost under the two situations for the two Type 2 cases are 




Intravenous glucose sensing and insulin delivery may be applied in closed-loop 
insulin delivery system for diabetic patients in intensive care unit. Intravenous glucose 
sensing providing glucose level in the bloodstream facilitates the controller to calculate 
more accurate insulin dosage and achieves tight glucose control. Intravenous insulin 
delivery shortens the time of insulin taking effect to stimulate glucose utilization. The 
intravenous-intravenous form of closed-loop insulin delivery can be simulated using the 
two-compartment model, which sets plasma glucose to be system output, and insulin 
infusion into plasma compartment to be system input. 
In Section 5.2, the two-compartment model proposed in Section 3.3 was used to 
design a controller, and the simulation results of glucose control were compared with that 
of a MPC controller using the Bergman minimal model. Four forms of glucose infusion:  
constant glucose infusion for 10 minutes for 3 times, constant glucose infusion, impulse 
glucose injection and exponentially decreasing glucose infusion, were included in the 
plasma compartment to compare the two models’ performance of regulating glucose level. 
It was demonstrated that the MPC controller using the two-compartment model shows 
some advantages over that of using minimal model: it causes less hypoglycemia and 
hyperglycemia, less insulin is used and glucose change caused by unnoticed glucose 
disturbance is better controlled.  
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Glucose measurement and insulin delivery in subcutaneous tissues is safe and 
convenient to be implemented in future artificial pancreas. A MPC controller using our 
model proposed in Section 4.3, which included the dynamics of glucose and insulin in 
subcutaneous tissues, was designed for glucose control, and the results are compared with 
that using Hovorka model for the three Type 1 cases. The initial conditions, value of 
model parameters and meal intake remained the same as that in Chapter 4. The two 
controllers were investigated for the performance of glucose regulation without and with 
unnoticed glucose disturbance in Section 5.3.  
Hyperglycemia and hypoglycemia often occurred to the system using Hovorka 
model controller, and insulin infusions calculated by the controller sometimes were 
unreasonable. The parameters’ value of Hovorka model was estimated with sparse 
glucose level measurements, which may cause the failure of glucose control using 
Hovorka model controller. Regardless of the inclusion of glucose disturbance, glucose 
regulated by the controller using our model proposed in Section 4.3 decreased from initial 
hyperglycemia fast and approached the ideal glucose level quickly, with negligible 
change around the ideal glucose level when glucose disturbance was introduced. 
Although the parameter value of model with subcutaneous insulin was estimated using 
the same clinical data with Hovorka model, the performance of glucose control using this 
model is good. Glucose control of the two Type 2 cases using this controller was studied 
following that of Type 1 cases. Glucose level was shown to be well regulated by the 
controller and insulin dosage calculated by the controller is much smaller than that used 
in the clinical observation. 
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Overall, the two-compartment model and the model with subcutaneous insulin 
proposed in this thesis were investigated for the performance of glucose control. 
Compared with the simulation results of glucose regulation of Bergman minimal model 





6 Conclusion and Future Work 
6.1 Conclusion 
Closed-loop insulin delivery system (also known as an artificial pancreas) could 
potentially be the ultimate solution for blood glucose control in diabetic patients, which is 
comprised of a glucose sensor for measuring glucose concentration, control algorithm for 
regulating insulin infusion, and an insulin infusion device for delivering insulin to the 
human body. MPC has been widely applied in glucose control. By developing an accurate 
glucose-insulin model, an efficient glucose control algorithm could be developed. 
Glucose measurement and insulin delivery in subcutaneous tissues has been applied 
to design artificial pancreas. A mathematical model of glucose-insulin system 
incorporating the dynamics of glucose and insulin in the subcutis is crucial for the 
investigation of glucose metabolism and MPC controller design. Based on existing 
studies on ultradian oscillations of glucose and insulin, a two-compartment model with 
two explicit delays on hepatic glucose production and insulin secretion was proposed in 
Chapter 3 to explore the oscillatory behavior of glucose-insulin system without external 
insulin delivery. Four model parameters in insulin subsystem, the two delays and glucose 
infusion rate were analyzed for their influence on the oscillations of glucose-insulin 
system. The irregular glucose level caused by different value of the model parameters 
was analyzed physiologically and related to diseases. Range of the model parameters 
were estimated for different cases: sustaining the oscillations of glucose and insulin level, 
Type 1 diabetes, Type 2 diabetes, and normal people. Three lags existing in the glucose-
insulin model were firstly investigated for the change with model parameters and related 
to the distribution and metabolism of glucose and insulin in different compartments. The 
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effect of the sum of the two delays was explored. It was proposed that delay-adjusting 
ability for normal people may regulate glucose level back to normal range quickly. 
However the delay-adjusting ability of delays may be impaired for diabetic patient to 
cause hypoglycemia or hyperglycemia. The characteristics of the model agree with most 
of the dynamic properties reported in literature, and support the hypothesis that the 
ultradian oscillation of glucose and insulin in human body may originate from the 
interaction and negative feedback between glucose and insulin. 
Type 2 diabetes is more prevalent and complex than Type 1 diabetes. There has not 
been a model of glucose-insulin system including the dynamics of subcutaneously-
injected insulin for Type 2 diabetic patients up to now. Therefore, developing a model to 
simulate the metabolism of glucose-insulin system including subcutaneously-delivered 
insulin for Type 2 diabetes is important for the derivation of control algorithm for 
automatic glucose regulation. Local degradation and time delay of transportation and 
absorption should be considered in the insulin module of the glucose-insulin system if 
exogenous insulin is injected in the subcutaneous tissues. Based on the two-compartment 
model, a modified model which includes two absorption channels and local insulin 
degradation was proposed to simulate the glucose-insulin system with external insulin 
injections in Chapter 4. The two rate parameters expressing insulin transportation from 
subcutis to plasma compartment, the two time delays and two parameters expressing the 
dysfunction of the diabetic patients were estimated using nonlinear least squares method. 
The clinical data of anonymous diabetes inpatients was collected, which comprised 
glucose level, insulin injection dosage and meals. Comparing the fitting results with that 
of Hovorka model, the proposed model was demonstrated to be able to mimic the 
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dynamics of glucose-insulin system based on long term clinical monitoring of diabetic 
subjects. The estimated model parameters were physiologically discussed. The discussion 
provided insights on the subject’s dysfunction caused by diabetes. Irregular oscillation of 
glucose level and influence of meals and insulin injections were observed in Type 2 cases. 
The effect of obesity and aging on the parameter value was investigated physiologically 
as well as based on the simulation result of the model. Due to obesity and aging, diffusion 
of injected insulin and glucose transport is slowed, insulin secreted by pancreas may be 
reduced, and insulin resistance becomes stronger resulting in lower glucose utilization. 
The aim of developing a mathematical model of glucose-insulin system is to study 
the physiological behaviors of the feedback system, as well as explore the approaches of 
controlling glucose level using the glucose-insulin dynamic model. MPC has been used in 
glucose level regulation. Insulin dosage calculated by the MPC controller is the input to 
the plant (i.e., human body). Glucose level was output and fed to MPC controller to 
calculate the next input iteratively. Glucose control using the two-compartment model 
proposed in Section 3.3 was used to mimic closed-loop insulin delivery with glucose 
measurement and insulin infusion intravenously, and compared with the simulation result 
of Bergman minimal model using different meal intakes. The model with subcutaneous 
insulin proposed in Section 4.3 was used to design a MPC controller, which simulated the 
closed-loop glucose control using glucose measurement and insulin delivery in the 
subcutaneous tissues. Simulation results of using this model were compared with that of 
Hovorka model. Comparing the simulation results using our proposed models with that of 
the two existing models, glucose level was demonstrated to be regulated within the 
desired glucose range using the two proposed models. The glucose curves and insulin 
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dosages of using these models to design MPC controller were compared to evaluate the 
performance of glucose control. It was shown that MPC controllers using our models are 
more advantageous for glucose regulation: fewer occurrences of hypoglycemia and 
hyperglycemia, less insulin cost and it can better deal with glucose changes caused by 
glucose disturbances. Simulation results demonstrated that the issues and challenges of 
using MPC on glucose control can be addressed adequately. The two-compartment model 
in Chapter 3 and the model with subcutaneous insulin in Chapter 4 proposed in the thesis 
could be applied in closed-loop insulin delivery system in future. 
 
6.2  Future Work 
6.2.1 Model Improvement 
In order to improve the controller performance, the model can be further explored. 
Other physiological and physical factor may be incorporated into the virtual patient 
model to better describe the metabolism of glucose of diabetic patients. 
FFA has been studied and modeled to make the virtual patient model closer to the 
human body. Oxidation of free fatty acids can be increased by increased rate of lipolysis 
in the adipose tissue during overnight fasting, starvation and exercise. The contribution of 
free fatty acids on the metabolism in the body and its interactions with glucose-insulin 
system is often ignored in the mathematical models which are mainly glucocentric. The 
dynamics of FFA was included in the Bergman minimal model, and its interaction with 
the dynamics of glucose and insulin was investigated for Type 1 diabetes in [42]. The 
plasma FFA, effect of remote FFA on glucose uptake, and effect of remote insulin on 
plasma FFA level were described by differential equations in this model. 
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Glucagon, secreted by α cells of pancreas, is another hormone important for 
glucose regulation. Glucagon is released to raise glucose level when glucose level is low 
by converting glycogen stored in the liver into glucose and delivered to the bloodstream. 
Both insulin and glucagon play an important role of maintaining stable glucose level. 
Present control studies focus on glucose and insulin as output and input respectively. 
Glucagon has been studied and incorporated into the mathematical models in some 
studies [14, 148, 149]. Glucagon may be utilized as another input in future controller 
design for its effect of preventing hypoglycemia. 
Exercise has significant influence on epinephrine. The metabolism of most tissue 
cells increases significantly with increasing epinephrine. Glucose production can be 
increased with increasing epinephrine level to provide energy during exercise, and 
glucose uptake into liver is decreased simultaneously. Two exercise models were 
proposed in [150, 151] respectively. Both models described increase of metabolic rates as 
a function of exercise level. The minimal model was extended to include the effect of 
exercise on plasma insulin clearance, elevation of glucose uptake and HGP rate in [150]. 
Mild and moderate intensity exercise was incorporated into an existing model for glucose 
metabolism in [151]. Increase in metabolic rates in both models was described by current 
oxygen consumption level as a percentage of maximum oxygen consumption level. In 
order to investigate the influence of exercise on glucose regulation, three parameters were 
introduced into minimal model to express the effect of exercise in accelerating glucose 
utilization by tissues, increasing insulin utilization and increasing sensibility of muscular 
and liver to the insulin action in [152] . 
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Further research on the effect of stress, sickness, exercise, etc. can provide more 
information about the interaction of these factors and pathology of diabetes. The 
incorporation of other hormones or physiological/physical states can increase the 
accuracy and applicability of the virtual patient model. 
 
6.2.2 Abnormalities of Ultradian Oscillations 
Many physiological and pathological factors can modulate or affect the ultradian 
oscillation of the glucose-insulin system. For non-diabetic people, the frequency of 
ultradian oscillation may be driven or affected by the exogenous disturbance such as 
oscillating glucose infusion [153]. The entrainment of ultradian oscillation and rapid 
oscillation was regarded as a feature of ultradian pulsatility; however, this feature is not 
for Type 2 diabetic patients [154, 155]. In this thesis, only constant glucose infusion was 
investigated for its effect on the ultradian oscillation. The investigation of ultradian 
oscillation of glucose and insulin focused on the influence of model parameters. Different 
forms of glucose infusion (e.g., oscillating, random glucose infusions, etc.) can be further 
explored for its effect on the ultradian oscillation. 
Ultradian oscillations of the non-diabetic obese people was proposed to have higher 
amplitude of oscillations without affecting the oscillation frequency, which was due to 
the impaired response of peripheral tissues to insulin [156]. For long-standing Type 2 
diabetes with the function of insulin secretion and action impaired, ultradian oscillation 
may be disrupted greatly, which showed irregular amplitude, frequency or concomitance 
of insulin and glucose [58]. Besides, oscillation of plasma glucose in Type 2 diabetes was 
observed to be broader and more sluggish, without sharp peaks. The reason may be the 
failure of insulin to suppress HGP and/or the insulin resistance in the periphery, which 
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results in diminished glucose utilization [58]. Further investigation based on Chapter 3 
and Chapter 4 can give insights on the effect of diabetes on ultradian oscillations. Loss of 
oscillation inducement for diabetic patients without exogenous insulin delivery may be a 
symptom of abnormality of the glucose-insulin system, and investigating ultradian 
oscillation and its entrainment using the two-compartment model may find some 
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